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Chapter 1. General Introduction 
Introduction to the Problem 
Porcine reproductive and respiratory syndrome virus (PRRSV) causes approximately 
560.32 million dollars in losses each year to US swine industry (Neumann et al., 2005). The 
virus causes reproductive failures in breeding age swine and respiratory diseases in growing 
pigs. PRRSV is the most common agent involved in the porcine respiratory disease 
complex; others include Mycoplasma hyopneumoniae, Pasteurella multocida, Actinobacillus 
pleuropneumoniae, Hemophilus parasuis, Streptococcus suis, swine influenza virus, porcine 
circovirus type 2, and pseudorabies virus. 
The adaptive immune response to PRRSV is weak and delayed, compared to adaptive 
immune response to other swine viral pathogens eg. pseudorabies virus and swine influenza 
virus. Antibody responses to PRRSV are predominately against non-neutralizing epitopes. 
Neutralizing antibodies to PRRSV have low neutralizing titers and appear late after infection. 
The antibodies provide complete protection only after homologous virus infection and partial 
or no protection after heterologous virus infection. Neutralizing antibodies at low titer may 
enhance PRRSV infection through antibody-dependent enhancement of infection. 
The cell-mediated immune (CMI) response to PRRSV is low in magnitude and also 
appears late after infection. Little is known about the specific T cell subsets required for 
protection from PRRSV-induced disease by T cells. The current methods utilized for 
detection of CMI response to PRRSV include lymphocyte blastogenesis, enzyme-linked 
immunospot (ELISPOT), and reverse transcriptase PCR and ELISA for detection of cytokine 
expression. Each method provides useful but incomplete data. Mechanisms that PRRSV 
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utilizes to delay CMI response and methods to improve CMI response to PRRSV have been 
poorly identified. 
Aims of the Present Studies 
The broad goal of the work presented in this dissertation was to evaluate CMI 
response to PRRSV. A four-color flow cytometry technique for detection of specific T cell 
subset response to PRRSV was developed and used in the experiments described in this 
dissertation. This technique allows simultaneous detection of 5 different porcine T cell 
subsets and the surface expression of CD25 molecules and intracellular expression of 
interferon gamma (IFNy). The first experiment described in this dissertation utilized four-
color flow cytometry technique to detect recall response of T cells after exposure to PRRSV 
antigens. Different vaccination strategies including PRRS modified-live virus (MLV) 
vaccine and various vaccine adjuvants as well as PRRSV peptide antigens were tested for 
their efficacy in inducing and enhancing the CMI response. T cell subsets responsible for 
protection from clinical disease were characterized. The second experiment described in the 
dissertation aimed at the ability of PRRSV to suppress T cell response in relation to the virus 
virulence and type of myeloid antigen-presenting cells the virus infects. 
Dissertation Organization 
Chapter 2 of the dissertation is a literature review of prior PRRSV research. 
Characteristics of the virus, pathogenesis of PRRSV-induced disease, immune response to 
PRRSV and PRRSV vaccines, and PRRSV immunity and protection are discussed in the 
review. Chapter 3 is a paper published in Veterinary Immunology and Immunopathology 
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(109: 99-115). Chapter 4 is a paper submitted to Viral Immunology. Chapter 5 is the 
conclusion of the Ph.D. dissertation and recommendations for future research in PRRSV 
immunology. 
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Chapter 2. Literature Review of Porcine Reproductive and 
Respiratory Syndrome Virus 
Characteristics of the Virus 
Virus Structure and Genomic Organization 
Porcine reproductive and respiratory syndrome virus (PRRSV) is a small, positive-
sense, single-strand enveloped RNA virus classified in genus Arterivirus, family 
Arteriviridae, order Nidovirales (Meulenberg et al., 1993). The viral genome is 
approximately 15 kb in size and is composed of 9 open reading frames (ORF), designated 
ORFla, lb, 2a, 2b, and 3-7 (Meulenberg et al., 1993). Genomic sequence analysis suggests 
the existence of at least 2 genotypes of PRRSV- the North American and the European-
which have 64-67% and 55-80% nucleotide sequence and amino acid sequence homology, 
respectively (Meng et al., 1995a; Meng et al., 1995b; Murtaugh et al., 1995; Nelsen et al., 
1999). 
ORFla and ORF lb encode viral RNA-dependent RNA polymerase (Allende et al., 
1999; Meulenberg et al., 1993). ORF2a and ORF3-5 encode glycosylated proteins, named 
GP2-GP5, respectively (Dea et al., 2000; Meulenberg and Petersen-den Besten, 1996; 
Meulenberg et al., 1995). ORF2b encodes unglycosylated 2b protein (Wu et al., 2001). 
ORF6 encodes an unglycosylated matrix (M) protein, which is connected by a disulfide bond 
to GP5 (Mardassi et al., 1996.; Meulenberg et al., 1995). ORF7 encodes an unglycosylated 
nucleocapsid protein (Meulenberg et al., 1995). 
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GP2, GP4, GPS, M, and probably GP3 are associated with the viral envelope (Dea et 
al., 2000). GP2, GP4, and GP5 contain minor T cell epitopes (Bautista et al., 1999). M 
protein contains major T cell epitope (Bautista et al., 1999). GP4 also contains a minor 
neutralizing epitope (Bautista et al., 1999; Kwang et al., 1999; Meulenberg et al., 1997; 
Weiland et al., 1999). The N-terminal ectodomain of GP5 contains the major neutralizing 
epitope (Gonin et al., 1999; Kwang et al., 1999; Ostrowski et al., 2002; Plagemann et al., 
2002; Weiland et al., 1999; Wissink et al., 2003). 
Among PRRSV isolates, GP5 has the highest amino acid sequence variation (81.96-
99.72% homology) (Kwang et al., 1999; Murtaugh et al., 1998; Pirzadeh and Dea, 1998; 
Weiland et al., 1999). M protein, on the other hand, has the least amino acid sequence 
variation (95.94-100% homology) (Allende et al., 1999; Kapur et al., 1996; Meng et al., 
1994; Meng et al., 1995a; Murtaugh et al., 1995). 
PRRSV Replication 
PRRSV infects myelomonocytic cell lineages, including monocytes, macrophages, 
and dendritic cells (Halbur et al., 1996a; Molitor et al., 1996; Thacker et al., 1998; 
Thanawongnuwech et al., 2000; Thanawongnuwech et al., 1997a; Voicu et al., 1994). 
Pulmonary alveolar macrophages (PAM) are the preferred target cells of PRRSV infection 
(Molitor et al., 1996). The virus enters the target cells by receptor-mediated endocytosis 
(Delputte and Nauwynck, 2004; Delputte et al., 2002; Duan et al., 1997; Nauwynck et al., 
1999; Vanderheijden et al., 2003). The process is mediated by two consecutive steps. First, 
the M or M-GP5 protein complex binds to heparan sulfate on target cell membrane (Delputte 
and Nauwynck, 2004; Delputte et al., 2002; Duan et al., 1997; Nauwynck et al., 1999; 
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Vanderheijden et al., 2003). Second, sialic acids on the virus envelope bind to sialoadhesins 
on the target cell membrane (Delputte and Nauwynck, 2004; Delputte et al., 2002; Duan et 
al., 1997; Nauwynck et al., 1999; Vanderheijden et al., 2003). 
Uncoating of PRRSV takes place in the endosome. This process is facilitated by the 
low pH in the endosome (Kreutz and Ackermann, 1996). The viral RNA is released from the 
endosome into the cytoplasm where the viral proteins are translated. The location of virus 
assembly is not known, but is likely to be in smooth endoplasmic reticulum (ER) (Pol et al., 
1997a). PRRSV obtains an envelope by budding through the membrane of the smooth ER 
(Dea et al., 1995; Mardassi et al., 1994; Pol et al., 1997a). The virus is released from the cell 
by cell lysis (Pol et al., 1997a). The replication cycle is approximately 9-12 hours (Pol et al., 
1997a). 
Characteristics of the Disease 
Effect of PRRSV on Immune Cells 
PRRSV suppresses phagocytic ability and inhibits microbial killing as well as 
production of reactive oxygen species eg. superoxide anion (O2") and hydrogen peroxide 
(H2O2) in infected PAM and pulmonary intravascular macrophages (PIM) (Chiou et al., 
2000; Thanawongnuwech et al., 1997a). PRRSV induces both infected cells and bystander 
uninfected cells, including lymphocytes, to undergo apoptosis (Sirinarumitr et al., 1998; 
Suarez, 2000; Sur et al., 1996; Sur et al., 1998). In in vivo observations, pigs infected with 
PRRSV develop transient monocytopenia and lymphopenia and have reduced numbers of 
PAM (Done and Paton, 1995; Rossow et al., 1994). PRRSV-induced apoptosis of infected 
cells was shown to be mediated by a product of ORF5 (Suarez et al., 1996). The expression 
of ORF5 protein under a T7 promoter in the recombinant vaccinia virus resulted in 
internucleosomal DNA degradation (apoptosis) in monkey BSC40 cells (Suarez et al., 1996). 
The precise mechanism of ORF5 protein induced apoptosis in infected and bystander 
uninfected cells is not known. Apoptosis of monocytes and macrophages, especially those of 
the respiratory system, results in increased susceptibility of pigs to secondary bacterial 
infections (Thanawongnuwech et al., 1997a; Thanawongnuwech et al., 1998a). 
Clinical Disease 
Pigs develop cell-free and cell-associated viremia within 24-96 hours after PRRSV 
infection (Christopher-Hennings et al., 2001; Halbur et al., 1996a; Halbur et al., 1995). The 
virus can be isolated from serum for at least 5 weeks after infection (Christopher-Hennings et 
al., 2001; Halbur et al., 1996a; Halbur et al., 1995). The virus spreads systemically to tissues 
including lung, heart, thymus, spleen, intestine, brain, testes, and ovaries within 48 hours of 
infection (Halbur et al., 1996a; Halbur et al., 1995; Rossow et al., 1994; Rossow et al., 1996; 
Sur et al., 1997; Sur et al., 2001; Thanawongnuwech et al., 1997b). 
Clinical disease induced by PRRSV varies significantly, depending upon virus 
genotype, virus virulence, and host factors ie. breed and age (Christopher-Hennings et al., 
2001; Halbur et al., 1996a; Halbur et al., 1995; Halbur et al., 1996b; Mengeling et al., 1998a; 
Opriessnig et al., 2002; Thacker et al., 1998; van der Linden et al., 2003). In general, North 
American PRRSV induces more severe clinical disease than European PRRSV (Labarque et 
al., 2002; Plana et al., 1992; Roof et al., 2003; van der Linden et al., 2003; Van Reeth et al., 
1996). Neonatal and nursery pigs manifest more severe clinical disease than older pigs (van 
der Linden et al., 2003). Neonatal and nursery pigs may experience high fevers, anorexia, 
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dyspnea, tachypnea, chemosis, conjunctivitis, and failure-to-thrive (Collins et al., 1992; 
Halbur et al., 1995; Halbur et al., 1996b; Rossow et al., 1994; van der Linden et al., 2003). 
Grow to finish pigs may experience respiratory disease that can vary from subclinical to fatal 
pneumonia (Collins et al., 1992; Halbur et al., 1995; Halbur et al., 1996b; Rossow et al., 
1994; van der Linden et al., 2003). Poor growth performance and mortality may result 
(Johnson et al., 2004). Breeding pigs may demonstrate late-term abortions, increased 
numbers of stillborn pigs, mummified fetuses, weak live-born piglets, and delayed return to 
estrus (Christiansen et al., 1992; Collins et al., 1992; Lager and Halbur, 1996b; Lager et al., 
1997a; Lager et al., 1997b; Mengeling et al., 1994; Mengeling et al., 1998b; Rossow et al., 
1996). Congenital infection can occur if sows are infected with PRRSV near farrowing (90 
days of gestation) (Lager et al., 1997a; Lager et al., 1997b). Piglets born from these sows can 
have viral RNA in their tissues until at least 210 days of age (Christopher-Hennings et al., 
1997). 
Pathological Lesion 
Gross and histopathological lesions caused by PRRSV are pronounced in two 
different organs- lung and lymphoid tissues (Halbur et al., 1995; Halbur et al., 1996b; 
Rossow et al., 1994). Pneumonia is primarily seen in the cranial, middle, and accessory 
lobes and the ventromedial portion of the caudal lobes of the lung and is characterized by 
failure of the lung to collapse, multifocal firmness, and tan discoloration (Halbur et al., 1995; 
Halbur et al., 1996b). Microscopic lesions are consistent with interstitial pneumonia, 
characterized by septal thickening with lymphocytes and macrophages, pneumocyte type 2 
hypertrophy and hyperplasia, and accumulation of normal and necrotic macrophages in 
alveolar spaces (Halbur et al., 1995; Halbur et al., 1996b; Rossow et al., 1994). The 
lymphoid tissues especially lymph nodes are enlarged due to polyclonal B-cell proliferation 
in lymphoid follicles in conjunction with infiltration of macrophages and lymphocytes into 
the follicles (Halbur et al., 1995; Halbur et al., 1996b; Lemke et al., 2004; Rossow et al., 
1994). Lymphocytes infiltrating into the lung and lymphoid follicles are predominately CD4 
CD8+ T cells (Tingstedt and Nielsen, 2004). Pyknotic macrophages are frequently observed 
in the lymphoid follicles (Halbur et al., 1995; Halbur et al., 1996b; Rossow et al., 1994). 
Other lesions may include rhinitis, encephalitis and myocarditis (Collins et al., 1992; Halbur 
et al., 1996a; Halbur et al., 1995; Halbur et al., 1996b; Rossow et al., 1994). 
Persistent Infection 
Pigs exposed to PRRSV demonstrate prolonged viremia (Albina et al., 1998b; 
Benfield et al., 1997; Foss et al., 2002; Mengeling et al., 1999; van der Linden et al., 2003; 
Wills et al., 1997). The virus can be isolated from serum and peripheral blood mononuclear 
cells (PBMC) of infected pigs until at least 5 weeks after infection and from tissues eg. heart, 
small intestine, and brain for days to months after infection (Christopher-Hennings et al., 
1997; Foss et al., 2002; Halbur et al., 1996a; Halbur et al., 1995; Rossow et al., 1994; Wills 
et al., 1997). The virus can be isolated from the palatine tonsils as long as 157 days after 
infection (Wills et al., 1997). During PRRSV infection, pigs may shed infectious virus via 
semen (Christopher-Hennings et al., 1995a; Christopher-Hennings et al., 1997; Christopher-
Hennings et al., 1995b; Nielsen et al., 1997b; Swenson et al., 1994), transplacental at late 
gestation (Lager et al., 1997a; Lager et al., 1997b), urine (Rossow et al., 1994; Wills et al., 
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1997), saliva (Wills et al., 1997), nasal secretions (Rossow et al., 1994), colostrum and milk 
(Wagstrom et al., 2001), and feces (Rossow et al., 1994; Wills et al., 1997). 
PRRSV Virulence 
In general, virulent PRRSV induces (1) more rapid and prolonged viremia and higher 
virus titers in the serum (Johnson et al., 2004; van der Linden et al., 2003), (2) more rapid 
and severe pneumonia, lymphadenopathy, encephalitis, and myocarditis and the lesions 
resolve faster (usually within 2-4 weeks after infection) (Halbur et al., 1996a; Halbur et al., 
1995; Halbur et al., 1996b), (3) more tissues infected and more virus antigens in each 
infected tissue (Halbur et al., 1996a; Haynes et al., 1997), (4) poorer growth performance and 
higher mortality rate especially in young pigs (Halbur et al., 1996a; Halbur et al., 1995; 
Halbur et al., 1996b), and (5) more rapid and higher magnitude of antibody response 
(Johnson et al., 2004; van der Linden et al., 2003) than low virulent PRRSV. 
PRRSV Immunity 
Innate Immune Response 
Pigs do not develop a good innate immune response after PRRSV infection. The 
level of type I interferon (IFN) was minimal or undetectable in serum and broncho alveolar 
lavage (BAL) fluid of PRRSV-infected pigs (Albina et al., 1998a; Van Reeth et al., 1999). 
PAM and PBMC do not produce IFNa in response to PRRSV infection (Albina et al., 
1998a). When PAM are infected with PRRSV and superinfected with transmissible 
gastroenteritis virus, a virus that strongly induces type I IFN production, no type I IFN can be 
detected (Albina et al., 1998a; Charley and Lavenant, 1990; Nowacki and Charley, 1993). 
Type I IFN production has been reported to be up-regulated after transmissible gastroenteritis 
virus, swine influenza virus, and porcine respiratory coronavirus (Albina et al., 1998a; 
Buddaert et al., 1998; Pfeffer et al., 1998; Van Reeth et al., 1999). 
The levels of pro-inflammatory cytokines ie. interleukin (IL)-l and tumor necrosis 
factor alpha (TNFa) were minimal in BAL fluid after PRRSV infection (Labarque et al., 
2003a; Van Reeth et al., 1999). IL-1 and TNFa were detected at high levels in BAL fluid 
after swine influenza virus infection (Van Reeth et al., 1999). PAM infected with PRRSV do 
not up-regulate IL-la and TNFa mRNA expression and TNFa protein production (Chiou et 
al., 2000; Lopez-Fuertes et al., 2000). In addition, PRRSV-infected PAM do not up-regulate 
TNFa mRNA expression in response to phorbol 12-myristate 13-acetate (PMA) plus calcium 
ionophore (ionomycin), a combination of potent TNFa inducers (Lopez-Fuertes et al., 2000). 
Humoral Immune Response 
Pigs develop antibodies to all structural proteins of PRRSV (Meulenberg et al., 1995). 
The majority of PRRSV-specific antibodies are against the nucleocapsid protein (Murtaugh 
et al., 1995; Plana-Dur an et al., 1997). These antibodies appear to develop faster than 
antibodies to other structural proteins (Nelson et al., 1994; Yoon et al., 1995; Loemba et al., 
1996). 
Total Antibody Response 
PRRSV-specific IgM can be detected in the serum and BAL fluid within 9 days of 
infection and last 3-4 weeks following infection (Joo et al., 1997; Labarque et al., 2000; 
Loemba et al., 1996; Park et al., 1995). PRRSV-specific IgA appears in serum and BAL 
fluid at 2 weeks after infection and decline to undetectable levels at about 6 weeks of 
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infection (Labarque et al., 2000). IgGl is the dominant isotype of PRRSV-specific antibody, 
arising at 9 days after infection and remaining at high titer in serum and BAL fluid (8-12 of 
log] titer) until at least 7-8 weeks after infection (Labarque et al., 2000). IgG2 is the second 
dominant isotype of PRRSV-specific antibody, appearing in the serum and BAL fluid at 2 
weeks after infection and remaining at considerable titers (6-8 of logz titer) until at least 7-8 
weeks after infection (Labarque et al., 2000). In a study that measuring the duration of 
antibodies, PRRSV-specific antibodies were detected in the serum by commercial EDEXX 
ELIS A for at least 210 days after infection (Wills et al., 1997). Specific antibodies are 
developed faster and at higher titers against virulent PRRSV isolates than attenuated ones 
(Johnson et al., 2004; van der Linden et al., 2003). 
Absence of an anamnestic antibody response was reported after a challenge with 
homologous virus as detected by IDEXX ELISA (Bassaganya-Riera et al., 2004; Foss et al., 
2002; Lager et al., 1997a; Lager et al., 1997b). In contrast, an anamnestic antibody response 
to original virus was detected after heterologous virus challenge (Botner et al., 1999; Nilubol 
et al., 2004). 
Neutralizing Antibody Response 
Neutralizing antibodies generally appear around 4 weeks after infection and persist at 
low titers (3-5 of logz titer) throughout the infection (at least until 210 days after infection) 
(Wills et al., 1997; Yoon et al., 1995). The neutralizing antibodies are directed against GP4 
and GP5 of the virus (Bautista et al., 1999; Gonin et al., 1999; Kwang et al., 1999; Ostrowski 
et al., 2002; Plagemann et al., 2002; Weiland et al., 1999; Wissink et al., 2003). Neutralizing 
antibodies can completely neutralize homologous virus but only partially (or not at all) 
neutralize heterologous virus (Lopez and Osorio, 2004). 
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Cell-Mediated Immune (CMI) Response 
In Vivo Response 
PRRSV causes a transient decrease of CD4+ and CD8+ T cells in peripheral blood 3 
days after infection (Nielsen and Botner, 1997a; Rossow et al., 1994; Shimizu et al., 1996). 
The decrease of CD4+ T cells lasts at least 2 weeks after infection, whereas the decrease of 
CD8+ T cells lasts 4 weeks after infection (Lamontagne et al., 2003; Shimizu et al., 1996). 
Following a decrease, the population of CD8+ T cells, primarily CD4"CD8+, increases 
significantly in peripheral blood and BAL fluid (Lamontagne et al., 2003; Samsom et al., 
2000; Shimizu et al., 1996). 
A delayed type hypersensitivity (DTH) response characterized by swelling and 
redness of the skin appeared 24 hours after intradermal challenge of PRRSV-infected pigs 
with UV-inactivated homologous virus (Bautista and Molitor, 1997). The DTH response 
declined 72 hours after the challenge (Bautista and Molitor, 1997). 
Lymphocyte Blastogenesis 
In vitro studies utilizing lymphocyte blastogenesis assay revealed that antigen-
specific lymphocytes appeared in the peripheral blood approximately 4 weeks after infection 
and persisted 3 months after infection (Bassaganya-Riera et al., 2004; Bautista and Molitor, 
1997; Lopez Fuertes et al., 1999). Secondary exposure to the homologous virus induced an 
anamnestic T-cell proliferative response in which T cells proliferated within 2 weeks after 
challenge (Bautista and Molitor, 1997). Analysis by flow cytometry revealed that the 
responsible T-cell subset for lymphocyte blastogenesis was CD4+CD8+ (Lopez Fuertes et al., 
1999). Other subsets of T cells that are responsible for T cell proliferation included CD8+ T 
cells which co-express y5 T-cell receptor (TCR) (Lopez Fuertes et al., 1999). 
Cytokine Response 
Primary exposure to PRRSV in vitro and in vivo induces an increase of IL-10 mRNA 
expression and IL-10 protein production in PBMC, BAL cells, and BAL fluid (Chung and 
Chae, 2003; Labarque et al., 2003a; Royaee et al., 2004; Suradhat and Thanawongnuwech, 
2003; Suradhat et al., 2003). No change or minimal and transient increase of IL-1, IL-2, IL-
4, IL-6, IL-8, IL-12, IL-15, IL-18, IFNy, and TNFa mRNA expression was detected in naïve 
PBMC incubated with PRRSV in vitro and PBMC collected from PRRSV-infected pigs 
(Chung and Chae, 2003; Feng et al., 2003; Royaee et al., 2004; Sipos et al., 2003; Suradhat et 
al., 2003). An elevation of IL-6 in serum has been reported in PRRSV-infected pigs (Asai et 
al., 1999; Feng et al., 2003). 
Piglets infected with PRRSV in utero demonstrated a significant increase of IL-6, IL-
10, and IFNy mRNA expression in their PBMC and BAL cells at the time of farrowing and at 
2 weeks of age (Feng et al., 2003; Johnsen et al., 2002). No change in IL-12 mRNA 
expression was observed in BAL cells at 2, 4, and 6 weeks after farrowing (Johnsen et al., 
2002). 
In vitro recall response to homologous PRRSV showed an increase of IFNy mRNA 
and protein and IL-2 mRNA expression, but not IL-4 mRNA expression, in PBMC (Foss et 
al., 2002; Lopez Fuertes et al., 1999; Meier et al., 2003; Royaee et al., 2004). IFNy-
producing PBMC determined by ELISPOT assay was detected after 4-8 weeks after PRRSV 
infection (Foss et al., 2002; Meier et al., 2003; Meier et al., 2004; Royaee et al., 2004). The 
numbers of IFNy-producing cells varied from 50-100 cells/106 PBMC at 4-10 weeks after 
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infection and gradually increased to approximately 400 cells/106 PBMC after 48 weeks of 
infection (Meier et al., 2003). The IFNy secretion was mediated primarily by CD4+CD8+ T 
cells as determined by a marked decrease of IFNy secretion after complement-mediated 
depletion of these cells (Meier et al., 2003). 
Immunity and Protection 
Innate Immunity 
The cytokines produced by innate immune cells ie. IFNa and TNFa have been 
demonstrated to have an inhibitory effect on PRRSV replication (Albina et al., 1998a; 
Buddaert et al., 1998; Lopez-Fuertes et al., 2000). Pre-treatment of PAM with recombinant 
porcine IFNa or TNFa significantly reduced PRRSV yield and the numbers of PRRSV-
infected cells (Buddaert et al., 1998; Lopez-Fuertes et al., 2000). Pre-inoculation in the lungs 
of pigs with porcine respiratory coronavirus, a potent IFNa inducer, followed 2 days later 
with PRRSV showed a significant reduction of PRRSV titers in the lungs, compared to those 
infected with PRRSV alone (Buddaert et al., 1998). No evidence of synergistic effect 
between IFNa and TNFa on inhibition of PRRSV replication was reported (Lopez-Fuertes et 
al., 2000). 
Humoral Immunity 
Humoral immunity has been reported to be a double-edged sword. The antibody may 
protect pigs from clinical disease or it may enhance PRRSV infection. This ambiguous 
effect of humoral immunity was demonstrated by Yoon et al (1996), whose study showed 
that pigs passively transferred with antiserum containing neutralizing antibody to PRRSV 
(VR-2402) at high neutralizing titer (1:16) were protected from viremia after homologous 
virus challenge. Pigs that received neutralizing antibody at lower titer (1:4), on the other 
hand, were not protected and had increased duration and level of viremia when compared to 
challenge control pigs. The increased viremia in the presence of low neutralizing antibody 
titers were suggested to be due to antibody-dependent enhancement of infection (Yoon et al., 
1996). 
The protection conferred by maternal-derived humoral immunity was elucidated by 
Osorio et al (2002). This study revealed that sows passively transferred with antiserum 
containing neutralizing antibody to PRRSV (97-7895) at neutralizing titer >1:256 at 87 days 
of gestation were completely protected from viremia and were negative for virus isolation 
from tonsils, lung, lung lavage, and lymph nodes after homologous virus challenge 3 days 
later. These sows passed neutralizing antibodies through colostrum and milk and yielded 
significantly higher viable piglets than challenge control sows. No PRRSV was isolated 
from the lung, lymph nodes, tonsils and spleen at 15 and 65 days of age in piglets born from 
these sows. 
Cell-Mediated Immunity 
The evidence of PRRSV-specific CMI conferring clinical protection is minimal. In in 
vitro studies, recombinant porcine IFNy was shown to inhibit PRRSV replication in 
monocytes, PAM, and monkey kidney cell line (MARC-145) (Bautista and Molitor, 1999; 
Rowland et al., 2001). The expression of IFNy in the recall reaction by PBMC of sows 
infected with PRRSV significantly correlates with protection from reproductive failure 
(Lowe et al., 2005). Sows that have higher numbers of IFNy-producing PBMC yield higher 
number of viable piglets at weaning than sows that have lower number of IFNy-producing 
cells (Lowe et al., 2005). IFNy-producing lymphocytes were recruited to the lungs after 
PRRSV infection (Thanawongnuwech et al., 2003). However their contribution to protection 
against respiratory disease has not been evident. 
PRRSV and Immunosuppression 
PRRSV has been presumed to possess immunosuppressive properties. This idea 
comes from at least 3 lines of evidence: 
(1) PRRSV-infected pigs seem to be more susceptible to co- and secondary infections 
and have more severe disease than pigs infected with co-infected pathogens alone. In field 
observations, PRRSV-infected pigs were demonstrated to have increased incidence of 
infections with Streptococcus suis, Hemophilus parasuis, Mycoplasma hyopneumoniae, 
Actinobacillus pleuropneumoniae, Salmonella spp., and swine influenza virus (Done and 
Paton, 1995; Rossow et al., 1995; Zeman et al., 1993). Experimental dual infection studies 
revealed that PRRSV exacerbated the severity of the disease caused by S. suis. Pigs infected 
with PRRSV and S. suis developed more severe suppurative meningitis and had higher 
numbers of S. suis in the brain, meninges, and blood than pigs infected with S. suis alone 
(Feng et al., 2001; Galina et al., 1994; Thanawongnuwech et al., 2000). 
(2) The immune response to PRRSV is delayed, compared to that to other pathogens 
(Thacker, 2001). 
(3) An IL-10 response dominates the response of other cytokines after PRRSV 
infection. The production of IL-10 is increased in BAL fluids of PRRSV-infected pigs 
(Chung and Chae, 2003; Johnsen et al., 2002; Labarque et al., 2003a; Thanawongnuwech and 
Thacker, 2003). IL-10 mRNA expression is increased in PBMC of PRRSV-infected pigs and 
naïve PBMC exposed to PRRSV in vitro (Royaee et al., 2004; Suradhat et al., 2003). IL-10 
has been demonstrated in pigs to have an inhibitory effect on IFNy production by T cells 
(Waters et al., 1999). It was shown in other species to have suppressive effects on T cell 
activation, cytokine production eg. IL-1, TNFa, IFNy, and activation of antigen-presenting 
cells (APC) (Moore et al., 2001). 
In contrast to this evidence, there are at least 2 lines of evidence that do not support 
the idea of PRRSV and immunosuppression. 
(1) Co-infection between PRRSV and H. parasuis (Cooper et al., 1995; Solano et al., 
1997), S. suis (Cooper et al., 1995), S. choleraesuis (Cooper et al., 1995), Pasteurella 
multocida (Carvalho et al., 1997; Cooper et al., 1995), M. hyopneumoniae (Thacker et al., 
1999; Van Alstine et al., 1996), A. pleuropneumoniae (Pol et al., 1997b), swine influenza 
virus (Pol et al., 1997b), and transmissible gastroenteritis virus (Wesley et al., 1998) did not 
exacerbate the severity of the disease caused by these pathogens. 
(2) Lack of evidence that pigs infected with PRRSV had impaired immune response 
to other pathogens. Pigs inoculated with PRRSV two weeks prior to immunization with 
killed pseudorabies virus (PRV) vaccine showed no significant difference in antibody 
response to killed PRV vaccine when compared to control pigs (Albina et al., 1998b). 
Instead, these PRRS V-infected pigs produced significantly higher antibody titers to PRV 1-2 
weeks after PRV challenge, compared to pigs not previously infected. No significant 
difference of DTH responses to intradermal challenge with PRV glycoproteins was observed 
between PRRSV-infected and control pigs (Albina et al., 1998b). No significant difference 
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on the antibody response to circovirus type 1 infection was observed between PRRS MLV-
vaccinated and control pigs (Foss et al., 2002). 
PRRSV Vaccines 
1. MLV Vaccine 
MLV vaccines used in the United States are derived from North American PRRSV 
isolate VR-2332 and JA-142 and are licensed under the trade name Ingelvac® PRRS MLV 
(licensed in 1994) and Ingelvac® PRRS ATP (licensed in 1999), respectively (Boehringer 
Ingelheim Vetmedica, Inc.). The Restriction Fragment Length Polymorphism (RFLP) 
pattern of ORF5 of Ingelvac® PRRS MLV and Ingelvac® PRRS ATP is 2-5-2 and 1-4-2, 
respectively (Roof et al., 2003). 
Ingelvac® PRRS MLV vaccine is recommended for use in sows, gilts, and piglets as 
an aid in the reduction of disease associated with PRRSV, reproductive and respiratory 
forms. In sows and gilts, the vaccine is recommended to be administered intramuscularly in 
a 2-ml single dose at 3-4 weeks prior to breeding and should be repeated prior to each 
subsequent breeding. In piglets, the vaccine is recommended to be injected intramuscularly 
in a single 2-ml dose at 3 weeks of age or older. 
Ingelvac® PRRS ATP is recommended for use only in pigs at 3-18 weeks of age as an 
aid in the reduction of respiratory disease associated with PRRSV. The vaccine is 
recommended to be injected intramuscularly in a single 2-ml dose at 3 weeks of age or older. 
Immune Response: 
Ingelvac® PRRS MLV vaccine induces both antibody and CMI responses. Specific 
antibody response detected by DDEXX ELIS A appears around 2 weeks after vaccination 
(Foss et al., 2002; Meier et al., 2004). Neutralizing antibody response arises around 4 weeks 
after vaccination (Meier et al., 2004). A CMI response determined by in vitro proliferation 
of peripheral blood T cells appears approximately 4 weeks after vaccination (Bassaganya-
Riera et al., 2004) and IFNy ELISPOT appears approximately 4-8 weeks after vaccination 
(Meier et al., 2003; Meier et al., 2004; Royaee et al., 2004). 
Protection: 
Homologous virus challenge: Pigs vaccinated with Ingelvac® PRRS MLV and 
challenged at 4 weeks after vaccination with vaccine parental strain (VR-2332) (99.7% 
ORF5-6 sequence homology to Ingelvac® PRRS MLV) were completely protected from 
viremia and demonstrated significant reduction of macroscopic lung lesions (Foss et al., 
2002; Roof et al., 2003). Reduced titers or no VR-2332 virus was shed in semen of boars 
vaccinated and challenged with VR-2332 at 50 days after vaccination (Christopher-Hennings 
et al., 1997). 
Complete protection from viremia after homologous virus challenge was a 
characteristic of PRRSV infection (Lager et al., 1997a; Lager et al., 1997b; Mengeling et al., 
1999; Mengeling et al., 2003a; Nielsen et al., 1997b; van Woensel et al., 1998). No PRRSV 
can be isolated from PAM, uterine lymph node, and tonsil after homologous virus challenge 
(Lager et al., 1997a; Lager et al., 1997b). One hundred per cent of fetuses at 111 days of 
gestation were protected from abortion, viremia, and were negative for virus isolation from 
PAM, lymph nodes, and tonsils when sows were challenged at 90 days of gestation (Lager et 
al., 1997a; Lager et al., 1997b; Mengeling et al., 1999). This protection was observed even 
when a homologous virus challenge was conducted 604 days after primary exposure (Lager 
et al., 1997a). 
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Heterologous virus challenge: Pigs vaccinated with Ingelvac® PRRS MLV or 
Ingelvac® PRRS ATP and challenged at 3 to 17 weeks after vaccination with heterologous 
virus eg. SDSU-73, 17198-6, MN/01/A1, NADC-8, NADC-9, NVSL-14, IA-1-4-2 or with 
European PRRSV showed reduced titers of viremia of challenged virus, fewer viremic pigs, 
and significantly reduced macroscopic lung lesions (Meier et al., 2004; Mengeling et al., 
1999; Mengeling et al., 2003b; Nielsen et al., 1997b; Nodelijk et al., 2001; Roof et al., 2003). 
The North American challenge PRRSV have 84.9%-91.7% ORF5-6 nucleotide sequence 
homology to the vaccine viruses (Roof et al., 2003). The protection from European PRRSV 
viremia by Ingelvac® PRRS MLV has not been consistent in all studies. Labarque et al 
(2003) reported that pigs vaccinated with Ingelvac® PRRS MLV and challenged at 6 weeks 
after vaccination with European PRRSV showed no reduction in number of viremic pigs and 
titer of challenged virus in serum and BAL fluid. 
Gilts vaccinated with Ingelvac® PRRS MLV vaccine and challenged 30 days later (at 
90 days of gestation) with heterologous PRRSV (NADC-8) showed shorter duration and 
reduced titers of viremia (Mengeling et al., 1999). There were fewer positive virus isolations 
from tonsil swabs and reduced numbers of pre- and postnatal deaths in vaccinated gilts in 
comparison to non-vaccinated challenge control gilts (Mengeling et al., 1999). Piglets born 
from MLV-vaccinated gilts were partially protected from virus infection as determined by 
negative virus isolation from tonsil swab and serum in some piglets (Mengeling et al., 1999). 
Piglets had higher body weight at 15 days of age than those born from non-vaccinated 
challenge control gilts (Mengeling et al., 1999). Boars vaccinated with Ingelvac® PRRS 
MLV vaccine and challenged 35 days later with European PRRSV showed reduction of virus 
shedding in semen (Nielsen et al., 1997b). 
Concerns of PRRSV MLV vaccine: 
Virus spreading: Ingelvac® PRRS MLV vaccine induces viremia after vaccination 
(Foss et al., 2002; Mengeling et al., 2003b; Nielsen et al., 1997b). The vaccine virus can be 
isolated from BAL fluid and serum at least 3 and 6 weeks after intramuscular injection, 
respectively (Mengeling et al., 2003b; Thacker et al., 2000). The virus can be shed in semen 
of boars up to 2 weeks after vaccination (Christopher-Hennings et al., 1997). The vaccine 
viral antigens and viral RNA can be detected in non-vaccinated boars that were housed in the 
same facility with boars previously immunized with Ingelvac® PRRS MLV (Botner et al., 
1997; Madsen et al., 1998). The vaccine virus spread from vaccinated pigs (3-18 weeks of 
age) to non-vaccinated sows in a different facility as determined by seroconversion of sows 
(Sorensen et al., 1998). 
Reversion to virulence: Ingelvac® PRRS MLV has been shown to revert to a state of 
virulence. Pregnant sows infected with vaccine virus which was shed from vaccinated pigs 
(3-18 weeks of age) demonstrated late-term abortion (Botner et al., 1997; Sorensen et al., 
1998). The vaccine-like virus was isolated from dead fetuses and piglets of these sows 
(Botner et al., 1997). The virus has 99.2-99.5% ORF2-7 nucleotide sequence homology to 
the Ingelvac® PRRS MLV (Madsen et al., 1998; Storgaard et al., 1999). Intranasal 
inoculation of vaccine-like virus isolated from dead piglets into seronegative sows at 90 days 
of gestation caused congenital infection, stillborn pigs, and high pre-weaning mortality 
(Nielsen et al., 2002). The vaccine-like virus, however, causes mild respiratory disease in 
growing pigs when compared to VR-2332 (Opriessnig et al., 2002). 
Poor immune response after long-term use: Multiple vaccinations with Ingelvac® 
PRRS MLV vaccine may result in absence of anamnestic LDEXX ELISA antibody and 
neutralizing antibody response as well as antigen-specific T cell proliferation (Bassaganya-
Riera et al., 2004; Osorio et al., 1998). Booster immunization with an inactivated genetically 
divergent virus has been reported to be helpful for boosting an antigen-specific T cell 
response (Bassaganya-Riera et al., 2004). The magnitude of antigen-specific T cell 
proliferation after booster immunization with inactivated heterologous virus, however, is still 
significantly lower than that obtained from animals vaccinating with Ingelvac® PRRS MLV 
for the first time (Bassaganya-Riera et al., 2004). 
2. Killed Virus (KV) Vaccine 
Commercial KV vaccine used in the United States is derived from North American 
PRRSV isolate VR-2402 (also known as ISUP) and is licensed under the trade name 
PRRomiSe™ (Intervet Inc.). The vaccine is recommended for use in female breeding age 
swine as an aid in the reduction of losses at farrowing due to PRRSV. The vaccine is 
recommended to be administered intramuscularly twice in a 2-ml dose; the first dose at 5-8 
weeks after breeding and the second dose at 2-4 weeks later. Vaccination is recommended to 
be repeated on subsequent breedings. The KV vaccine is adjuvanted with Spur (Intervet's 
Proprietary Technology) to enhance the immune response. 
Immune Response: 
PRRomiSe™ vaccine did not induce antibody responses detectable by IDEXX 
ELISA and serum virus neutralization (SVN) test (Bassaganya-Riera et al., 2004). The 
vaccine induces a CMI response determined by in vitro CD8aP T cell proliferation which can 
be detected 27-38 days after the first dose of vaccination (Bassaganya-Riera et al., 2004). 
Repeated vaccination of PRRomiSe™ vaccine generates poorer antigen-specific T cell 
proliferation (Bassaganya-Riera et al., 2004). 
Protection: 
Little data is available regarding PRRomiSe™ vaccine's efficacy. An experiment 
conducted in Europe, using European strain of PRRSV as a source of experimental 
inactivated PRRSV vaccine demonstrated the protection from reproductive failures in sows 
and gilts previously infected with field European PRRSV. The number of stillborn pigs and 
mummies were significantly reduced after 3 doses of inactivated PRRSV vaccine (Reynaud 
et al., 1998). The health status of piglets born from vaccinated and experimentally 
challenged sows was improved in comparison to those born from non-vaccinated sows 
(Plana-Duran et al., 1997b). 
Experimental killed PRRSV vaccine (VR-2402) appeared to decrease the duration of 
viral shedding in the semen of boars experimentally infected with homologous PRRSV (VR-
2402) (Swenson et al., 1995). PRRomiSe™ vaccine, however, did not protect pigs from 
viremia and virus infection in tonsils when pigs were infected with heterologous virus (VR-
2385) (Nilubol et al., 2004). Pigs demonstrated increased neutralizing antibody titers to VR-
2385 after PRRomiSe™ vaccination (Nilubol et al., 2004). 
Concerns of PRRSV KV vaccine: 
Poor CMI response after long-term use: The main attribute of killed PRRSV vaccine 
is to boost neutralizing antibody response, not CMI response (Bassaganya-Riera et al., 2004). 
Multiple vaccinations with PRRomiSe™ vaccine resulted in poor antigen-specific T cell 
proliferation. Sows that were repeatedly vaccinated with PRRomiSe™ and boosted with 
Ingelvac® PRRS MLV showed some improvements of magnitude of antigen-specific T cell 
proliferation. However, such response was still significantly lower than that observed in 
naïve sows receiving PRRomiSe™ vaccination for the first time (Bassaganya-Riera et al., 
2004). 
3. DNA Vaccine 
A plasmid DNA expressing PRRSV ORF was studied for its efficacy in inducing 
immune responses and protecting pigs from clinical disease after PRRSV challenge. The 
advantage of DNA vaccine over PRRSV MLV is its safety (no virus shedding and reversion 
to virulence). In addition, DNA vaccines could ideally elicit immune response to various 
PRRSV isolates in one vaccination. The DNA vector contained immunostimulatory CpG 
motifs which enhance CMI response in pigs (Kamstrup et al., 2001). 
Immune Response: 
Administration of the DNA vaccine induced both antibody and CMI responses 
(Barfoed et al., 2004a; Kwang et al., 1999; Pirzadeh and Dea, 1998). Pigs receiving 
intramuscular and intradermal injections of plasmid DNA (100 (a.g) encoding PRRSV ORF5 
developed neutralizing antibodies and in vitro T cell proliferation (Pirzadeh and Dea, 1998). 
Pigs injected intramuscularly with 400 gg of DNA encoding PRRSV ORF4-7 developed 
neutralizing antibody and antibody detectable by IDEXX ELIS A and Western blot assay, T-
cell proliferation, and IFNy production (Kwang et al., 1999). Pigs vaccinated with 10.8 fxg of 
gold particle-coated DNA encoding ORF 1-7 developed an antibody response to only ORF7 
products (Barfoed et al., 2004a). 
Protection: 
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Pigs immunized with DNA vaccine may be protected from viremia and respiratory 
lesions after homologous virus challenge (Barfoed et al., 2004a; Pirzadeh and Dea, 1998; 
Rompato et al., 2006). Pigs vaccinated by gene gun containing 60 pg plasmid DNA 
encoding ORF7 of PRRSV (MI 1257) (2 times, 3-week interval) and intranasally challenged 
at 4 weeks after the last vaccination with homologous virus (MI 1257) showed reduced virus 
load in the serum, compared to unvaccinated control pigs (Rompato et al., 2006). Pigs 
vaccinated intramuscularly and intradermally with DNA encoding ORF5 of PRRSV (Quebec 
IAF-Klop) (3 times at 2-week intervals) and intratracheally challenged at 2 weeks after the 
last vaccination with homologous virus showed reduced macroscopic and microscopic lung 
lesions (Pirzadeh and Dea, 1998). The challenge virus was isolated only from lung and 
mediastinal lymph nodes with reduced virus titers, while in unvaccinated control pigs, the 
virus was isolated from lung, spleen, kidney, liver, mediastinal and mesenteric lymph nodes 
(Pirzadeh and Dea, 1998). Intradermal vaccination with gold particle-coated plasmid DNA 
encoding ORF 1-7 of European PRRSV (DK-111/92) (6 times, 3-week interval) and 
intranasally challenged at 3 weeks after the last vaccination with homologous virus showed 
no protection from viremia in term of duration (Barfoed et al., 2004a). 
Concerns of PRRSV DNA vaccine: 
Difficulty in administration: The administration of DNA vaccine has limited 
practical application. Studies by Barfoed et al (2004b) reported that pigs vaccinated with 
plasmid DNA encoding ORF7 of European PRRSV (DK-111/92) 4 times at 3-week intervals 
developed higher antibody response detected by whole PRRSV (DK-11 l/92)-coated ELIS A 
when they were vaccinated by gene gun than by conventional intramuscular and intradermal 
injection. The sites of vaccination by gene gun were the dorsal side of the ear, the inguinal 
area, the dorsal thorax, and the ventral side of the tongue (Barfoed et al., 2004b). The 
intramuscular and intradermal routes of plasmid DNA administration, which are more 
practical, require 100 times more DNA per vaccination than vaccination by gene gun in order 
to obtain the same level of antibody response (Barfoed et al., 2004b). 
4. Recombinant PRRSV Protein Vaccine 
Recombinant PRRSV protein was studied for its potential use as a subunit vaccine. 
Immune Response: 
Administration of recombinant PRRSV protein in PRRSV-seronegative pigs induces 
both antibody and CMI responses (Pirzadeh and Dea, 1998; Plana Duran et al., 1997a). 
Intramuscular and intradermal injections with 300 (ig ORF5 proteins joined at the N-
terminus with glutathione S-transferase (GST-ORF5) 3 times at 2-week intervals induced a 
neutralizing antibody response (titer <1:8) and lymphocyte blastogenesis (Pirzadeh and Dea, 
1998). Intramuscular injection with Sf9 cells infected with recombinant baculovirus 
expressing ORF7 of European PRRSV in the form of water/oil/water emulsion in pregnant 
sows at 30 and 51 days of gestation induced an antibody response as detected by an 
immunoperoxidase monolayer assay (IPMA) (Plana Duran et al., 1997a). Anamnestic 
antibody responses were detected after the second vaccination. 
Protection: 
No clear protection from respiratory lesions conferred by recombinant PRRSV 
protein vaccine was observed after homologous virus challenge. Pigs vaccinated 
intramuscularly and intradermally with 300 |ig GST-ORF5 of PRRSV (Quebec IAF-Klop) 3 
times at 2-week intervals and intratracheally challenged 2 weeks after the last vaccination 
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with homologous virus (Quebec IAF-Klop) showed no protection from macroscopic and 
microscopic lung lesions when compared to unvaccinated challenge control pigs (Pirzadeh 
and Dea, 1998). The challenge virus was isolated from lung, spleen, kidney, and mediastinal 
lymph nodes with no or slight reduction of virus load when compared to unvaccinated 
challenge control pigs (Pirzadeh and Dea, 1998). 
Some protection from reproductive failure was observed after vaccination with cells 
expressing recombinant PRRSV proteins. Sows vaccinated intramuscularly with Sf9 cells 
infected with recombinant baculovirus expressing ORF3, ORF5, and/or ORF7 of European 
PRRSV (Olot/91) in the form of water/oil/water emulsion at 30 and 51 days of gestation and 
intranasally challenged at 70-90 days of gestation with homologous virus (Olot/91) showed 
some protection from reproductive failure. The percentage of piglets born alive after virus 
challenge was highest in ORF3 sows (68.4%), ORF5 sows (50%), and ORF7 sows (16.6%), 
respectively. The percentage of piglets bom alive in ORF7 sows, the only group that showed 
an antibody response after vaccination, was not different from that of unvaccinated challenge 
control sows (12.9%) (Plana Duran et al., 1997a). 
Adjuvants for PRRSV Vaccine 
Immune responses elicited by PRRSV vaccines are relatively weak and delayed, 
compared to those induced by other virus vaccines eg. pseudorabies and swine influenza 
(Thacker, 2001). Various reagents have been tested for their potential as adjuvants for 
PRRSV vaccine. These immune mediators included cytokines (IL-l/IL-6 combination, IL-2, 
IL-4, IL-12, IFNa), synthetic double-stranded RNA (poly ICLC), and cholera toxin. 
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Combination of IL-1 and IL-6 
IL-1 has been reported in mice to be effective in eliciting in vivo expansion and 
follicular migration of antigen-stimulated T cells (Pape et al., 1997), causing IL-12-induced 
IFNy production by natural killer cells (Hunter et al., 1995), and enhancing antibody 
production (Reed et al., 1989). Adjuvant properties of IL-1 were demonstrated in swine in 
conjunction with a Streptococcus suis vaccine (Blecha et al., 1995). Pigs administered 
recombinant IL-1 at 10 ng/kg body weight had higher antibody responses to S. suis, less 
severe clinical disease and macroscopic lesions after challenge, and better growth 
performance during infection. 
IL-6 has been reported to promote the terminal differentiation of activated B cells into 
antibody-secreting cells in mice (Diehl and Rincon, 2002; Kammuller, 1995). This cytokine 
has an inhibitory effect on T helper 1 (Thl) differentiation (Diehl and Rincon, 2002). In 
pigs, the adjuvant properties of IL-6 have been tested with swine influenza virus vaccine 
(Larsen and Olsen, 2002). Administration of an IL-6 expressing plasmid during vaccination 
for swine influenza virus did not enhance vaccine efficacy for inducing antibody responses 
and protection after swine influenza virus challenge (Larsen and Olsen, 2002). 
In PRRSV, a combination of recombinant porcine IL-1 and IL-6 was studied as an 
adjuvant for PRRSV MLV vaccine. Pigs vaccinated with Ingelvac® PRRS MLV which 
received Pichia pasfom-expressed recombinant porcine IL-1 and IL-6 at the time of 
vaccination and at 2, 4, and 7 days after vaccination (20 \ig of each cytokine at each time 
point) showed no improvement in kinetics and magnitude of antibody response detected by 
IDEXX ELIS A and CMI response detected by IFNy ELISPOT when compared to those of 
animals vaccinated with Ingelvac® PRRS MLV alone (Foss et al., 2002). 
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IL-2 
IL-2 has been identified as one of the major cytokines responsible for the regulation 
of CMI responses (Arai et al., 1990; Gaffen and Liu, 2004). The cytokine has been 
extensively studied as a vaccine adjuvant in mice, rhesus macaque, cattle, and pigs (Chow et 
al., 1998; Derosa and Sordillo, 1997; Kim et al., 1999; Kim et al., 2001; Mbawuike et al., 
1990; Wong et al., 2002). It has been shown that when multiple injections of IL-2 are 
administered after the immunizing antigen, protection against challenge is enhanced (Derosa 
and Sordillo, 1997; Mbawuike et al., 1990). The co-administration of a plasmid containing 
the swine IL-2 gene along with a foot-and-mouth DNA vaccine was able to significantly 
increase the stimulation index of T cells, when compared to those of animals vaccinated with 
the DNA vaccine alone (Wong et al., 2002). 
Pigs immunized with PRRSV-ORF7 DNA vaccine and DNA encoding porcine IL-2 
at day -1,0 (vaccination day), and 1 (60 |a.g each) and received booster immunizations with 
both DNA constructs 21 days later demonstrated a significant increase in T cell proliferation 
when compared to T cells of pigs immunized with plasmid DNA encoding ORF7 alone 
(Rompato et al., 2006). 
IL-4 
IL-4 has been reported to be effective in promoting proliferation of resting B cells 
(Arai et al., 1990), production of antigen-specific antibody (Kim et al., 1999; Kim et al., 
2000), and differentiation of ThO into Th2 cells (Paul, 1991). Adjuvant properties of IL-4 
were demonstrated in rhesus macaque in conjunction with a DNA vaccine encoding simian 
immunodeficiency virus Gag/Pol proteins. Rhesus macaques administered DNA expressing 
IL-4 had increased levels of antigen-specific antibodies, when compared to those of animals 
receiving DNA vaccine alone (Kim et al., 1999). 
In PRRSV, plasmid DNA encoding porcine IL-4 did not have adjuvant properties 
when administered with DNA vaccine expressing PRRSV ORF7 (Rompato et al., 2006). In 
addition, T cell proliferation was shown to be decreased after homologous PRRSV challenge 
when compared to T cells of pigs immunized with PRRSV DNA vaccine alone (Rompato et 
al., 2006). 
IL-12 
IL-12 has been reported to induce IFNy expression in T cells and natural killer cells 
in humans, mice, and pigs (Cho et al., 1996; Domeika et al., 2002; Perussia et al., 1992). In 
pigs, recombinant human IL-12 was studied as a vaccine adjuvant for inactivated PRV 
vaccine (Zuckermann et al., 1998). Pigs vaccinated with inactivated PRV and recombinant 
human IL-12 at 2 hours before and 2 hours after vaccination (2 |ig each) demonstrated a 
significant increase in number of IFNy-secreting PBMC as determined by ELISPOT, 
compared to pigs that received inactivated PRV vaccine alone (Zuckermann et al., 1998). 
The amino acid sequences of human and porcine IL-12 have 85% homology (Foss and 
Murtaugh, 1997). 
In PRRSV, recombinant porcine IL-12 has been reported to increase the number of 
IFNy-producing PBMC after Ingelvac® PRRS MLV vaccination. Pigs vaccinated with 
Ingelvac® PRRS MLV and Pichia pastoris-expressed recombinant single-chain (p70) porcine 
IL-12 at the time of vaccination and at 2, 4, and 7 days after vaccination (20 jag each) had 
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significantly increased numbers of IFNy-secreting PBMC as determined by ELISPOT, 
compared to pigs vaccinated with Ingelvac® PRRS MLV alone (Foss et al., 2002). 
Recombinant porcine IL-12 given with Ingelvac® PRRS MLV did not increase antibody 
response as determined by IDEXX ELISA (Foss et al., 2002). 
IFNa 
IFNa has been reported to promote the expression of MHC class I and class II as well 
as co-stimulatory molecules in monocytes, dendritic cells, and B cells of mice, and thereby 
enhance the activity in antigen presentation and T cell activation (Honda et al., 2003; 
Kadowaki et al., 2000; Montoya et al., 2002; Pogue et al., 2004). The cytokine has been 
demonstrated to enhance IFNy expression in CD4+ T cells of humans and mice (Biron, 2001; 
Brinkmann et al., 1993; Consens et al., 1999). 
IFNa has been studied as a vaccine adjuvant for PRRSV vaccines as IFNa production 
is reduced after PRRSV infection and vaccination (Albina et al., 1998a; Buddaert et al., 
1998; Royaee et al., 2004; Van Reeth et al., 1999). It has been thought that the exogenous 
addition of this cytokine might compensate for this deficiency and thus may stimulate CMI 
after PRRSV MLV vaccination. 
Pigs vaccinated with Ingelvac® PRRS MLV and a plasmid expressing porcine IFNa 
at the time of vaccination (200 |ig) demonstrated a significant increase in numbers of IFNy-
secreting PBMC when compared to pigs vaccinated with Ingelvac® PRRS MLV alone (Meier 
et al., 2004). The increased response was detected between 2 and 6 weeks after vaccination. 
No differences in antibody responses determined by IDEXX ELISA were observed between 
those two groups (Meier et al., 2004). 
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Poly ICLC 
Poly ICLC (polyinosinic:polycytidylic complexed with poly-L-lysine and 
carboxymethylcellulose) is a synthetic double-stranded RNA reported to effectively induce 
type I EFN production in humans, mice, and pigs (Finkelman et al., 1991 ; Loewen and 
Derbyshire, 1988a; Loewen and Derbyshire, 1988b; Weingartl and Derbyshire, 1990). In 
pigs, poly ICLC has been studied for its adjuvant activity with PRRSV MLV vaccine (Meier 
et al., 2004). Pigs vaccinated with Ingelvac® PRRS MLV and poly ICLC at the time of 
vaccination (0.25 mg/kg body weight) had a significant increase in numbers of IFNy-
secreting PBMC when compared to pigs vaccinated with Ingelvac® PRRS MLV alone (Meier 
et al., 2004). The significantly increased response was detected between 1 and 3 week after 
vaccination. No differences in antibody responses as measured by IDEXX ELISA were 
observed between those two groups (Meier et al., 2004). 
Cholera toxin (CT) 
CT has been reported to promote production of proinflammatory cytokines (IL-1, IL-
6, IL-12), expression of co-stimulatory molecules on PBMC and macrophages of humans, 
mice, and pigs, antigen presentation and T cell proliferation, and isotype switching of murine 
B cells (Bromander et al., 1991; Cong et al., 1997; Foss and Murtaugh, 1999b; Foss and 
Murtaugh, 1999c; Foss et al., 1999a; Krakauer, 1996; Lycke and Strober, 1989). 
The use of CT as a vaccine adjuvant for PRRSV vaccine was reported by Foss et al 
(2002). Pigs vaccinated with Ingelvac® PRRS MLV and CT at the time of vaccination and at 
2, 4, and 7 days after vaccination (20 p.g each) showed improved kinetics and magnitude of 
the anti-GP5 antibody response. The response was detected at 21 days after vaccination 
whereas the maximum response of anti-GP5 antibody to MLV alone was at 28 days (Foss et 
al., 2002). CT did not improve the CMI response as determined by IFNy ELISPOT when 
compared to the response to the MLV vaccine alone (Foss et al., 2002). 
Overview of Porcine Myeloid Antigen-Presenting Cells (APC) 
Monocytes 
Porcine monocytes constitute 10-15% of peripheral blood leukocytes and about 10-
40% of PBMC (Chamorro et al., 2005). Monocytes are derived from myeloid progenitors in 
the bone marrow. They and other myeloid cells express swine workshop cluster 3 (SWC3+), 
a molecule that is specific for cells of myeloid lineage of pigs (Chamorro et al., 2005; 
McCullough et al., 1999; McCullough et al., 1997). Monocytes express high levels of 
SWC1, MHC class I, MHC class II and CD14 (Basta et al., 1999). The expression of SWC1, 
MHC class II, and CD 14 is down-regulated after monocytes differentiate to macrophages 
(Basta et al., 1999). No expression of the co-stimulatory molecule CD80 is reported on 
monocytes of pigs (Basta et al., 1999). 
Monocytes are a potent producer of IL-1 either spontaneously or after activation by 
bacterial lipopolysaccharide (LPS) (Basta et al., 2000; Basta et al., 1999). The cells respond 
to bacteria, virus, and plasmid DNA antigens by expression of IL-6, IL-10, and IL-12 
(Johansson et al., 2003). Monocytes also are strong inducers of T cell proliferation in recall 
responses even in the absence of co-stimulatory molecules (Basta et al., 1999). This is 
probably due to the high IL-1 producing-characteristics of the cells (Basta et al., 1999). 
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Macrophages 
Macrophages are derived from peripheral blood monocytes upon migration into 
tissues. The cells can also be derived in vitro from blood monocytes by continuous plate 
adherence (Basta et al., 1999; McCullough et al., 1999; McCullough et al., 1997). 
Monocyte-derived macrophages (MDM) express a specific molecule, SWC9+, which is not 
present in monocytes (McCullough et al., 1999; McCullough et al., 1997). The expression of 
this molecule increases during the differentiation process of MDM. MDM express high 
levels of MHC class I, CD80, and [31/(32 integrins and low levels of MHC class II and CD14 
(Basta et al., 1999). Phagocytosis and endocytosis and several enzyme activities (eg. acid 
phosphatase and glucuronidase) are increased whereas some (eg. nucleotidase, peroxidase, 
myeloperoxidase, and esterase) are decreased when compared to monocytes (Basta et al., 
1999). 
MDM are not good IL-1 producers. The level of IL-1 mRNA and protein expression 
is low, compared to that of monocytes (Basta et al., 1999). MDM have poorer efficacy in 
inducing T cell proliferation in a recall response in comparison to monocytes (Basta et al., 
1999). 
Like MDM, PAM express the SWC1"SWC9+ phenotype (Basta et al., 1999). PAM 
express MHC class I, MHC class II, CD80 and (31/(32 integrins to the same level as MDM 
(Basta et al., 2000; Basta et al., 1999). However, PAM are incapable of inducing T cell 
proliferation in recall responses (Basta et al., 2000). This is probably due to the poor IL-1 
production and other unidentified suppressive effects in PAM (Basta et al., 2000). 
Dendritic cells 
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Porcine dendritic cells are derived from myeloid progenitors in the bone marrow. 
The cells have a characteristic phenotype of enlarged cell diameter, pronounced profusions 
and microvillous projections of plasma membrane, and abundant multivacuolar and 
multilamellar vesicles (Johansson et al., 2003; Paillot et al., 2001). The dendritic cells can be 
derived in vitro from bone marrow progenitor cells and peripheral blood monocytes by 
continuous culture in complete media supplemented with recombinant porcine granulocyte-
macrophage colony stimulating factor (GM-CSF) and recombinant porcine IL-4 and/or 
recombinant human TNFa (Johansson et al., 2003; West et al., 1999). The resulting 
monocyte-derived dendritic cells (MDD) are in an immature state (Johansson et al., 2003). 
The immature MDD have a strong ability to take up foreign antigens (Johansson et al., 2003). 
The antigen uptake capacity decreases as the cells maturate. The maturation of MDD can be 
induced by LPS, TNFa, and other necrotic factors (Paillot et al., 2001). MDD express IL-6, 
IL-10, IL-12, and IFNa in response to bacteria, virus, and plasmid DNA (Johansson et al., 
2003). MDD have the ability to induce T cell proliferation in a mixed leukocyte reaction 
(Johansson et al., 2003; West et al., 1999). This ability is seen more potently in mature MDD 
than immature MDD (Paillot et al., 2001). 
MDD express MHC class I, MHC class II, CD80, CD86, p2-integrins, CD1, CD36, 
CD68 (lysosome-associated membrane glycoprotein), and p55 fascin (actin-bundling protein) 
(Johansson et al., 2003; Paillot et al., 2001). Expression of p55 fascin is found only in MDD 
but not in MDM (West et al., 1999). The expression of MHC II, CD80, and CD86 of MDD 
are up-regulated upon their differentiation from monocytes (Johansson et al., 2003). The 
expression of CD 14 is down-regulated during differentiation from monocytes (Paillot et al., 
2001). 
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Summary 
The humoral and cell-mediated immune responses to PRRSV are weak. The 
antibody response to PRRSV is predominantly against non-neutralizing epitopes. Antibodies 
against neutralizing epitopes appear later than non-neutralizing antibodies and have low 
neutralizing titers throughout the course of infection. The CMI response appears at the same 
time or later than neutralizing antibodies and has a lower magnitude, compared to the CMI 
response to other swine viral pathogens. 
Protection of pigs by antibodies is restricted by antigenic variation of PRRSV 
neutralizing epitopes. The antibodies provide complete protection only from homologous 
virus challenge and partial or no protection from heterologous virus challenge. Low titers of 
neutralizing antibody enhance PRRSV infection through an antibody-dependent 
enhancement of infection of macrophages. 
Little is known about T cell subsets specific for PRRSV after infection or vaccination 
and the protection conferred by T cells. Mechanisms that PRRSV utilizes to impair CMI 
responses and methods to improve CMI response to PRRSV are not well understood. 
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Chapter 3. Immune Responses and Protection by Vaccine and Various 
Vaccine Adjuvant Candidates to Virulent Porcine Reproductive and 
Respiratory Syndrome Virus 
A paper published in Veterinary Immunology and Immunopathology * 
Wasin Charerntantanakul, Ratree Piatt, Wesley Johnson, Michael Roof, 
Eric Vaughn, James A. Roth 
Abstract 
Various vaccine adjuvant candidates were assessed with the modified-live porcine 
reproductive and respiratory syndrome virus (MLV PRRSV) (Ingelvac® PRRS MLV) 
vaccine. Their influence on humoral-mediated immune (HMI) and cell-mediated immune 
(CMI) responses as well as protection from virulent PRRSV challenge (MN-184) was 
evaluated. Ninety seronegative pigs were randomly divided into 9 groups of 10 pigs. One 
group received MLV vaccine alone. Five groups received MLV vaccine with either bacterial 
endotoxin-derived adjuvant (ET), mixed open reading frame 5 (ORF5) peptides derived from 
various PRRSV isolates, porcine interferon alpha (IFNa), polyinosinic-polycytidylic acid 
stabilized with polylysine and carboxymethylcellulose (poly-ICLC), or porcine interleukin-
12 (IL-12). One group did not receive MLV vaccine but was immunized with ORF5 
peptides conjugated with cholera toxin (ORF5 
* Reprinted from volume 109, pages 99-115, © 2006, with permission from Elsevier. 
peptide/CT). Two groups served as challenged and unchallenged non-vaccinated controls. 
Four-color flow cytometry was utilized to simultaneously identify 3 major porcine T-cell 
surface markers (CD4, CDS, and yô TCR) and detect activation marker CD25 (a chain of IL-
2 receptor) or intracellular IFNy. The MLV PRRSV vaccine alone successfully primed CD4" 
CD8+yô~ T cells as demonstrated by a significant increase in %IFNy+ cells when live PRRSV 
was used as a recall antigen. Booster immunizations of mixed ORF5 peptides and co­
administration of IL-12 with MLV PRRSV vaccine significantly enhanced IFNy expression 
by some T cell subsets (CD4~CD8+yô+ and CD4"CD8"y8+ for mixed ORF5 peptides and 
CD4+CD8+y5" and CD4"CD8+y§+ for IL-12). All groups receiving MLV-vaccine with or 
without adjuvants had reduced lung lesions after challenge. The group immunized with only 
ORF5 peptide/CT did not have significant T cell recall responses and was not protected from 
challenge. Expression of IFNy by several T cell subsets correlated with reduced lung lesions 
and viremia, whereas expression of CD25 did not. Expression of surface CD25 did not 
correlate with IFNy production. PRRSV ELISA s/p ratio prior to challenge also correlated 
with reduced lung lesions and viremia. In conclusion, booster immunizations of the mixed 
ORF5 peptides and co-administration of IL-12 effectively enhanced the CMI response to 
MLV vaccine. However, neither adjuvant significantly contributed to reducing clinical 
effects when compared to MLV alone. 
Keywords: Vaccine adjuvant; Porcine reproductive and respiratory syndrome virus; 
Humoral-mediated immune response; Cell-mediated immune response 
Abbreviations: PRRSV, porcine reproductive and respiratory syndrome virus; CMI, cell-
mediated immunity; HMI, humoral-mediated immunity; MLV, modified-live virus; ET, 
bacterial endotoxin-derived adjuvant; 0RF5, open reading frame 5; Poly-ICLC, polyinosinic-
polycytidylic acid stabilized with polylysine and carboxymethylcellulose; ORF5 peptide/CT, 
ORF5 peptides conjugated with cholera toxin; MFIs, geometric mean fluorescent intensities; 
CD25EI, CD25 expression index; EMEM, Eagle's minimum essential medium 
1. Introduction 
Porcine reproductive and respiratory syndrome virus (PRRSV) is a linear positive-
sense, single-stranded, enveloped RNA virus of the family Arteriviridae (Meulenberg et al., 
1993). The viral genome is approximately 15 kb in size and consists of 9 open reading 
frames (ORFs), designated ORE la, lb, 2a, 2b, and 3 to 7 (Conzelmann et al., 1993; 
Meulenberg et al., 1993). ORF5 encodes a major envelope glycoprotein containing a 
neutralizing epitope(s) (Pirzadeh and Dea., 1997; Kwang et al., 1999; Ostrowski et al., 2002; 
Plagemann et al., 2002). 
PRRSV has been recognized as the causative agent of reproductive failure in adult 
pigs and respiratory disease in young pigs (Christiansen et al., 1992; Collins et al., 1992; 
Halbur et al., 1996). A modified-live virus (MLV) PRRSV vaccine has been used to control 
PRRSV infection. The vaccine induces both humoral-mediated immune (HMI) and cell-
mediated immune (CMI) responses (Foss et al., 2002; Meier et al., 2003). MLV-vaccinated 
pigs showed reduced lung lesions (Mengeling et al., 2003) and were protected from viremia 
after homologous virus challenge (Foss et al., 2002). Antibody responses to MLV vaccine 
detected by ELIS A test appear within 14 days post vaccination, while neutralizing antibodies 
arise at 4 weeks post inoculation (Yoon et al., 1995; Foss et al., 2002). Vaccine-induced 
CMI, determined by enzyme-linked immunospot (ELISPOT) assay for IFNy production, 
appears at low level at 14 days post vaccination and develops slowly (Foss et al., 2002; Meier 
et al., 2003). Vaccine provides incomplete protection to heterologous PRRSV infections 
(Labarque et al., 2003). 
Efforts to use immunomodulating agents to induce robust HMI and CMI responses to 
vaccine antigens have been attempted for some swine diseases, eg. cholera toxin (CT) for 
Ascarid suum antigens (Tsuji et al., 2001) and IL-12 for inactivated pseudorabies virus 
vaccine (review in Zuckermann et al., 1999). A recent study by Foss et al. (2002) showed 
the contributions of CT and IL-12 to the MLV PRRSV vaccine in accelerating neutralizing 
antibody production and enhancing IFNy production by PBMCs, respectively. 
Various vaccine adjuvants were evaluated in this study for their efficacy to induce 
more potent HMI and CMI responses to the MLV PRRSV vaccine and to protect pigs from 
virulent PRRSV challenge. The adjuvants included bacterial endotoxin-derived adjuvant 
(ET), mixed ORF5 peptides derived from various PRRSV isolates, porcine IFNa, 
polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-
ICLC), and porcine IL-12. 
The responsive T-cell subsets to the recall vaccine antigens were identified by a four-
color flow cytometry technique, which allows simultaneous detection of 3 T-cell surface 
markers (CD4, CDS, and yS TCR) and surface CD25 (the alpha chain of IL-2R) or 
intracellular IFNy. We also correlated the responsive T-cell subsets, and the ELIS A s/p ratio, 
with lung lesions and viremia after virulent virus challenge. 
2. Materials and methods 
2.1 Experimental design 
Ninety 3-week-old PRRSV-seronegative pigs were randomly divided into 9 groups of 
10 pigs. Each group was housed in a separate pen at the Veterinary Resources Inc. facilities 
(Cambridge, IA). Groups receiving MLV vaccine were in separate rooms from groups not 
receiving MLV vaccine. The non-challenged group was isolated from the challenged groups. 
Groups 1 to 6 were vaccinated i.m. with 2 ml of Ingelvac® PRRS MLV (Boehringer 
Ingelheim Vetmedica, Inc. (BIVI), St. Joseph, MO). The vaccination day was referred to as 
day 0 of the experiment. In addition to Ingelvac® PRRS MLV (group 1), groups 2 to 6 also 
received different vaccine adjuvants i.m. at different sites of injection than MLV vaccine. 
Group 2 received a 2 mL dose of ET (BFVI, St. Joseph, MO) on day 0, group 3 received 1 ml 
dose of mixed ORF5 ectodomain peptides derived from 5 PRRSV isolates (Ingelvac® PRRS 
MLV, SDSU-73, 17198-6, JA142wt, and MN/01/A1), on day 14 and 28, group 4 received 1 
x 105 units of porcine IFNa (PBL Biomedical Laboratories, Piscataway, NJ) on day -1,0, and 
1, and a 400 |ig dose of IFNa DNA vaccine on day 0 (Zuckermann F., University of Illinois, 
Urbana, IL), group 5 received a 0.4 mg dose of poly-ICLC (Ribopharm, Inc. Bethesda, MD) 
on day 1, and group 6 received a 4.0 jxg dose of porcine IL-12 (R&D Systems, Minneapolis, 
MN) on day 1. Group 7 was immunized i.m. with a 60 pig dose of mixed ORF5 ectodomain 
peptides conjugated with CT (Sigma, St.Louis, MO) on day 0, 14, and 28. The ORF5 
peptides were derived from the same PRRSV isolates as was group 3. Group 8 served as 
mock negative control, received 2 ml i.m. of Eagle's minimum essential medium (EMEM) 
(JRH Bioscience, Lenexa, KS). Group 9 served as a strict control without any treatment. All 
groups except group 9 were challenged intranasally with 105'0 tissue culture infectious dose 
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50 (TCDD50) of PRRSV isolate MN-184 on day 55. The experimental design is summarized 
in Table 1. All pigs were necropsied on day 69. 
2.2 Viruses 
PRRSV isolate MN-184, SDSU-73, and vaccine strain (Ingelvac® PRRS MLV, serial 
no. JA-787-645, BIVI, St. Joseph, MO) were cultured in confluent MARC-145 cells grown 
in tissue culture media (DMEM"; DMEM (Life Technologies, Gaithersburg, MD) with 10% 
heat-inactivated FBS (Atlanta biologicals, Norcross, GA) and 1% tissue culture penicillin 
(10,000 IU/ml)/streptomycin (10,000 fig/ml) (P/S; Mediatech, Inc., Hemdon, VA)). The 
cultures were incubated in a humidified 5% CO2 atmosphere at 37°C for 3 days or until 60-
80% of cytopathic effect (CPE) were observed. Infected cultures were frozen and thawed, 
and centrifuged at 1,200 rpm and 4°C for 10 minutes. The supernatant was collected, 
aliquotted into small volumes, and stored at -80°C. Virus titration was performed by indirect 
immunofluorescent assay (IFA), using PRRSV-specific mouse mAbs (clone 15E) (Piatt KB., 
Iowa State University, Ames, IA), and FITC-conjugated anti-mouse IgG antibodies (Sigma, 
St.Louis, MO). Mock antigens were prepared in the same fashion as virus antigens except 
the viruses were absent. 
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Table 1. Summary of experimental treatments. 
Group N Antigen 
(Day 0) 
Adjuvants Timing of 
adjuvants 
Challenge 
MN-184 
1 10 MLV - - Day 55 
2 10 MLV ET Day 0 Day 55 
3 10 MLV ORF5 peptides Day 14,28 Day 55 
4 10 MLV IFNa Day -1,0,1 Day 55 
5 10 MLV Poly-ICLC Day 1 Day 55 
6 10 MLV IL-12 Day 1 Day 55 
7 10 ORF5 
peptide/CT - Day 0,14,28 Day 55 
8 10 EMEM - - Day 55 
9 10 
2.3 Adjuvants and antigen 
0RF5 ectodomain peptides were derived from 5 PRRSV isolates, including Ingelvac® 
PRRS MLV (VLANASNDSSSHLQLIYNLK), SDSU-73 (VLVNANNSSSS-
HFQSIYNLK), 17198-6 (VLVDANSNSSSHFQLIYNLK), JA142wt (ALVNANSN-
SSSHLQLIYNLK), and MN/Ol/Al (ALVNADSNSSSHLQLIYNLK). To couple CT with 
the peptides, CT were reduced with 50 mM of 1,4-Dithio-DL-threitol (DTT) solution at 37°C 
for 1 hour and were run over PD-10 desalting column (Amersham, Piscataway, NJ) to 
remove DTT. Peptides were mixed with sulfo-SMCC (Sulfosuccinimidyl 4-[N-
maleimidomethyl] cyclohexane-1 -carboxylate) dissolved in DMSO and were coupled with 
CT at 4°C overnight. The protein concentrations were determined by bicinchoninic acid 
(BCA) protein assay. 
2.4 Virology 
2.4.1 Virus isolation 
Virus isolations were performed with 100 pi of sera collected on days 55, 56, 59, 62, 
and 69 in duplicate wells on 48 well plates containing confluent CL 2621 cells. The cells 
were grown in EMEM supplemented with 2% heat-inactivated FBS, 50 (xg/mL Gentamicin 
(Sigma, St. Louis, MO), and 2.5 p.g/mL Fungizone (Invitrogen, UK). The plates were 
incubated at 37°C with 4.5% CO2 for 8 days. At the end of incubation, each well was 
examined for CPE and the percent positive in each group was calculated. 
2.4.2 Viremia detection by real-time RT-PCR 
Real-time RT-PCR was only performed on sera collected on day 69. The extraction 
of viral RNA was performed using the QIAamp Viral RNA Mini-Kit® (Qiagen, Valencia, 
CA) as described in the kit instructions. The real-time RT-PCR assay kit for PRRSV 
detection was purchased from Tetracore Inc. (Gaithersburg, MD) and used according to kit 
instructions. 
2.5 Serology 
Sera from all pigs were collected on day 0 and every week after vaccination until 
virus challenge (day 55). After challenge, sera were collected on day 56, 59, 62, and 69. 
Antibodies specific to PRRSV were measured by 2 serological assays; ELISA (HerdChek®, 
IDEXX Laboratories, Westbrook, ME) and serum virus neutralization (SVN) test. Results of 
ELISA were presented according to the manufacturer's protocol as the sample to positive 
(s/p) ratio, where s/p ratio equal to and greater than 0.4 was considered positive. SVN test 
was performed on sera collected on day 0 and every other week. The test was performed as 
described by Yoon et al. (1995). PRRSV isolates MN-184 and SDSU-73 were used as viral 
antigens. SVN titer equal to or greater than 4 was considered positive (Christopher-Hennings 
et al., 2001). 
2.6 Cell-mediated immunity 
2.6.1 Isolation of PBMC 
Whole blood of all animals was collected on day 0, 28, 42, 55, and 69 days post 
vaccination and transferred into a BD Vacutainer™ CPT™ with sodium citrate (Pharmingen, 
San Diego, CA), and centrifuged at 2,500xg at room temperature for 30 minutes. Two ml of 
PBMC at the interface were collected into a 14 ml polypropylene centrifuge tube (BD, 
Franklin Lakes, NJ) and contaminating RBCs were lysed with 6 ml of buffered water for 90 
seconds. The isotonicity was restored with 3 ml of 3x PBS. PBMC were centrifuged at 
1,250 rpm at 4°C for 15 minutes and washed once with PBS. After final wash, PBMC were 
resuspended in 3 ml RPMI^ (RPMI-1640 with 25mM HEPES and L-glutamine (Life 
Technologies, Gaithersburg, MD), 10% heat-inactivated FBS, and 1% P/S). Cells were 
counted, using automatic cell counter (Beckman coulter, Inc., Fullerton, CA), and adjusted to 
5 x 106 cells/ml in RPMI++. 
2.6.2 PBMC culture and stimulation 
PBMC from each pig were cultured in 2 identical sets in 96-well tissue culture flat-
bottomed plates (BD Labware, Franklin Lakes, NJ). One set was for CD25 staining and the 
other was for intracellular IFNy staining. In each set, 106 PBMC in 200 pi RPMI++ was 
added into 4 wells. Each well received 100 jj.1 of either 102 TCID^/ml of vaccine virus, 
RPMI4"* (unstimulated control), mock antigen (mock control), or ConA (positive control) at 
final concentration of 1 (ig/ml. Plates were incubated in a humidified 5% CO] atmosphere at 
37°C for 5 days. Wells to be stained for intracellular IFNy received 50 gl of GolgiStop 
solution (Pharmingen, San Diego, CA) diluted in RPMI++ at a final concentration 
recommended by the manufacturer at 12 hours before staining. PMA (Sigma, St.Louis, MO) 
and ionomycin (Sigma, St.Louis, MO) diluted in RPMI++ at final concentration of 7 ng/ml 
and 430 ng/ml, respectively, were added to positive control wells at the same time. 
2.6.3 Antibodies 
Primary mAbs included mouse anti-porcine CD4a mAbs (clone 74-12-4, isotype 
IgG2b), mouse anti-porcine CD8a mAbs (clone 76-2-11, isotype IgG2a), FITC-conjugated 
mouse anti-5 chain of porcine yô TCR (clone PGBL22A, isotype IgGl) (VMRD, Pullman, 
WA), and R-phycoerythrin (R-PE)-conjugated mouse anti-porcine CD25 mAbs (clone 
PGBL25A, isotype IgGl) (VMRD, Pullman, WA). The former two mAbs were produced in 
our laboratory by hybridoma cells purchased from American Type Culture Collection 
(ATCC) (Manassas, VA). The latter two mAbs were custom-conjugated with FITC and R-
PE, respectively (Chromaprobe, Maryland Heights, MO). Secondary antibodies comprised 
Alexa Fluor®647-conjugated goat anti-mouse IgG2a (y2a) antibodies (Molecular Probes, 
Eugene, OR) and Tri-color®-conjugated goat anti-mouse IgG2b (y) antibodies (Caltag 
Laboratories, Burlingame, CA). R-PE-conjugated mouse anti-porcine IFNy mAbs (clone 
P2G10, isotype IgGl) (BD Pharmingen, San Diego, CA) were used for intracellular IFNy 
staining. 
2.6.4 Fluorescent antibody labeling 
Fresh cell staining: Prior to PBMC culture, lxl 06 cells of freshly isolated PBMC 
from every pig were transferred to 96-well round-bottomed tissue culture plates (BD 
Labware, Franklin Lakes, NJ) and stained for CD4, CDS, yô-TCR, and CD25 as described 
below. 
Cultured cell staining: At the conclusion of the culture period, the culture plates were 
chilled on ice for 15 minutes. PBMC were mixed gently with a micropipette and transferred 
correspondingly to 96-well round-bottomed plates, centrifuged at 1,200 rpm and 4°C for 1 
minute, and washed twice with cold PBS++ (PBS with 0.5% FBS, and 0.1% sodium azide 
(Sigma, St.Louis, MO)). For surface CD25 staining, 50 pi of a mixture of four primary 
mAbs at their previously titrated optimum dilutions was added to all wells, and incubated in 
the dark at 4°C for 30 minutes. PBMC were then centrifuged at 1,200 rpm and 4°C for 1 
minute. The supernatants were discarded and PBMC were washed three times with PBS""", 
and incubated with 50 p.1 of a mixture of two secondary antibodies at their previously titrated 
optimum dilutions in the dark at 4°C for 30 minutes. PBMC were washed twice with PBS""" 
and once with PBS then fixed with 150 jj.1 of 1% ultrapure formaldehyde (Polyscience, 
Warrington, PA) in PBS. 
For intracellular IFNy staining, PBMC were stained in the same fashion as that for 
CD25 staining except the primary mAb mixture contained no anti-CD25 mAbs. After 
washing off secondary antibody conjugates, PBMC were stained for intracellular IFNy, BD 
Cytofix/Cytoperm kit (Pharmingen, San Diego, CA) was used according to the 
manufacturer's protocol. Briefly, PBMC were fixed with 100 JJ.1 BD Cytofix/Cytoperm 
solution for 20 minutes at 4°C, centrifuged at 1,200 rpm and 4°C for l minute, washed twice 
with BD Perm/Wash solution, incubated 30 minutes with 50 |a.l R-PE-conjugated mouse anti-
porcine IFNy mAbs diluted in BD Perm/Wash at previously titrated optimum dilution, 
washed three times with BD Perm/W ash, and fixed with 1% ultrapure formaldehyde in PBS. 
Single-color control, secondary antibody control, unstained cells, isotype controls, 
and unlabeled antibody blocking controls for IFNy staining, using unlabeled mouse anti-
porcine IFNy mAbs (clone P2G10, isotype IgGl) (BD Pharmingen, San Diego, CA), 
followed by R-PE-conjugated mouse anti-porcine IFNy mAbs were performed. The fixed 
cell suspensions from both stainings were transferred to 5 ml polystyrene round-bottom tubes 
(BD, Franklin Lakes, NJ) and kept at 4°C until flow cytometric analysis. 
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2.6.5 Flow cytometry 
The flow cytometric analysis was performed by the flow cytometry facility at Iowa 
State University. Four-color analysis was performed on an Epics Altra cytometer (Beckman 
Coulter, Fullerton, CA) equipped with both krypton (488 nm) and helium-neon laser (633 
nm). The FITC, R-PE, and Tri-Color® dyes were excited by the same 488 nm krypton laser. 
Alexa Fluor®647 dye was excited by a spatially separated 633 nm helium-neon laser. A 
gated amplifier was used to differentiate Tri-Color® and Alexa Fluor®647 signals, which 
were detected by the same photomultiplier tube. 
Analysis of flow cytometry data was performed, using Flow Jo analysis software 
(Tree Star, Inc. San Carlos, CA). The analysis targeted five major porcine T-cell subsets; 
CD4+CD8yS", CD4+CD8+y8", CD4"CD8+yô\ CD4"CD8+yô+, and CD4"CD8yS+, and a non T-
cell subpopulation (CD4"CD8"y8~). To analyze an individual data set, a dot plot of peak 
forward scatter versus linear forward scatter was plotted to gate out doublet events. A dot 
plot of linear side scatter versus linear forward scatter of single cells was applied to select 
live cell populations. Quadrant markers were set on CD4 versus CD8 T cells, generating 4 
defined lymphocyte subsets containing CD4+CD8", CD4+CD8+, CD4"CD8+, and CD4 CD8". 
Histogram based on yô fluorochrome (FITC) was applied to each subset. A histogram gate 
separated y8+ and y8" populations and further identified 4 original T-cell subsets into 8 
subsets. Two minor subsets, CD4+CD8"y8+ and CD4+CD8+y8+, each represented less than 
0.5% of the whole live cell population (Table 2), were not further analyzed. The remaining 6 
subsets were gated for their EFNy+ or CD25+ percentage on a histogram based on IFNy or 
CD25 fluorochrome (R-PE), respectively. The percentage of positive cells of each subset 
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and their geometric mean fluorescent intensities (MFIs) of the R-PE fluorochrome were 
collected from all samples. 
2.6.6 Expression index (EI) of CD25 and percentage of IFNy+ cells 
The EI of CD25 was calculated as previously described by Sandbulte and Roth 
(2002). Briefly, products from the multiplication of %CD25+ and MFI of each subset were 
obtained. The EI derived from dividing the "product" of antigen-stimulated cells by the 
"product" of unstimulated cells of the same subset of the same animal. Results from IFNy 
staining were presented as percentage of positive cells (%IFNy+) of the same subset. 
2.7 Immunity index calculation 
An immunity index was calculated to determine if it would be a better predictive 
indicator for clinical protection from virulent virus challenge. It represents both HMI and 
CMI collectively. The HMI was represented by the s/p ratio obtained from ELISA test on 
day 55 (prior to virus challenge). The CMI was represented by the %IFNy+ calculated for all 
PBMCs and for 5 individual T-cell subsets and a non T-cell subset averaged from day 42 and 
55, which were time points when increased IFNy responses were observed. The ELISA s/p 
ratios were multiplied by 10 to weigh their values to similar levels as the %IFNy+ cells. The 
immunity index was calculated for each T cell subset for each animal using the following 
formula: 
Immunity index = (s/p ratio x 10) + (%IFNy+ cells by individual T cell subset) 
2.8 Necropsy and lung lesion scoring 
Necropsy was performed on day 69. Pigs were euthanized by electric shock and lung 
lesions were determined as described by Halbur et al (1996). The total score of apical, 
cardiac, and diaphragmatic lobes on each side were 10%, 10%, and 25%, respectively and the 
intermediate lobe was 10%. 
2.9 Statistical analysis 
The CD25EI and %IFNy+ data for each PBMC subset from day 42 and 55 post 
vaccination were tested for statistical difference by two-way analysis of variance (ANOVA), 
followed by Dunnett's test using mean of group 1 and group 9 as control groups. Means of 
CD25EI and %IFNy+ shown in the figures were averaged from data of day 42 and 55 post 
vaccination. Lung lesion scores of every group were tested for statistical difference by one­
way ANOVA, followed by Dunnett's test using mean of group 1 and group 8 as control 
groups. The percentage of virus-positive pigs, number of PRRSV copies, and immunity 
index were tested for statistical significance in the same way as lung lesion scores except 
mean of group 1 and group 9 were used as controls. The percentage of virus-positive pigs of 
each group was averaged from data collected on day 59, 62, and 69. The negative and 
positive results were defined to be 0 and 1, respectively. Pigs that were positive for virus 
isolation for 3, 2, and 1 time points were defined to be 100%, 66.7%, and 33.3% positive, 
respectively. The number of PRRSV copies was transformed to logio prior to analysis and 
value of 0 was defined to be 1 prior to logio transformation. The SVN titers were 
transformed to log? to calculate the log mean titer of each group. Anti-log transformation 
was applied to obtain the final mean titer of each group. The CD25EI and %IFNy+ data 
averaged from day 42 and 55 post vaccination were used for correlation analyses with lung 
lesion scores and number of PRRSV copies. P<0.05 was set as statistically significant level 
throughout this study. » 
3. Results 
3.1 Sensitivity of four-color flow cytometry 
Six major subsets of PBMC, consisting of 3 subsets of a|3 T cells (CD4+CD8"yô~, 
CD4+CD8+y8", CD4'CD8+y6"), 2 subsets of y8 T cells (CD4"CD8+yÔ+, CD4"CD8"yô+), and 1 
subset that did not express any of the 3 surface markers, denoted CD4"CD8~yô", were detected 
by four-color flow cytometry. The percentage of each PBMC subset was calculated from 
non-vaccinated pigs (n=20) on day 42 and 55 of the experiment. The CD4+CD8"yô+ and 
CD4+CD8+yô+ subsets made up less than 0.5% of the PBMCs, so no further analysis was 
performed on those subsets. The percentage of other subsets was comparable to previously 
reported values for the same age group (Stabel et al., 2000). The percentage of CD4"CD8"yô" 
subset decreased after 5 days of incubation with or without antigen. This may have resulted 
from the adherence of monocytes/macrophages (CD4"CD8"yô ) to the culture plate. The 
percentage of the remaining y§" subsets did not perceptibly change after culture whereas the 
CD4"CD8+yô+ and CD4"CD8"yô+ had a marked increase (Table 2). 
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Table 2. PBMC were collected on day 42 and 55 post vaccination from non-vaccinated 
groups (group 8 and 9), stained immediately or after 5-day culture with culture media or 
vaccine virus with mAbs directed to surface T-cell subset markers, followed by flow 
cytometric analysis. Shown are mean percent + SEM of PBMC subsets before and after 5-
day culture of total live cells (n=20). 
Day 0 Day 5 (media) Day 5 (Ag-stimulated) 
a(3 T cells 
CD4+CD8"yS" 10.1 ± 1.0 9.9 ±0.9 8.4 ±0.8 
CD4+CD8+y8" 4.5 ± 0.3 5.7 ±0.5 6.1 ±0.7 
CD4"CD8+yô" 15.2 ±0.9 15.0 ±0.7 14.7 ±1.2 
y§ T cells 
CD4+CD8"yô+ 0.2 ±0.0 0.4 ±0.0 0.4 ±0.1 
CD4"CD8+yô+ 2.2 ±0.2 8.8 ±0.8 8.8 ±0.6 
CD4"CD8"yô+ 16.5 ± 1.0 26.1 ± 1.6 29.8 ±1.9 
CD4+CD8+yô+ 0.2 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 
Non-T cells 
CD4"CD8"yô" 51.3 ± 1.2 33.9 ±2.3 31.5 ± 1.8 
3.2 Antibody responses 
All pigs were seronegative to PRRSV by ELISA test on the vaccination day (day 0) 
and remained seronegative until day 14 post vaccination when some MLV-vaccinated pigs 
became seropositive (Fig. 1). By day 28, all MLV-vaccinated pigs (group 1 to 6) were 
seropositive and remained seropositive throughout the study with no significant difference 
among mean s/p ratio (p>0.05). All ORF5 peptide/CT pigs (group 7) remained seronegative 
until two weeks after the virus challenge (day 55). Challenge control pigs (group 8) became 
seropositive on day 69, while strict negative control pigs (group 9) remained seronegative 
throughout the study. No significant difference among mean s/p ratios from virus-challenged 
groups (groups 1 to 8) was found on day 69 (p>0.05). 
The SVN test was performed in parallel with the ELISA test, using sera collected on 
day 0 and every other week until day 69. The neutralizing activities of the sera were tested 
with 2 field strain viruses, MN-184 and SDSU-73. Prior to virus challenge, there were no 
detectable neutralizing antibodies to either strain of virus in any group (data not shown). 
After challenge with strain MN-184 on day 55, neutralizing antibodies to the homologous 
strain were detected on day 69 in all MLV-vaccinated groups and one pig each from ORF5 
peptide/CT group and challenge control group. The antibody titers ranged from 4 to 32 and 
the percentage of pigs showing neutralizing antibodies ranged from 40% in MLV-vaccinated 
pigs with IFNa (group 4) to 100% in MLV vaccine alone (groups 1), MLV-vaccinated pigs 
with ET (group 2), and MLV-vaccinated pigs with mixed ORF5 peptides (group 3). Cross-
neutralizing antibodies to heterologous strain SDSU-73 were detected only in MLV-
vaccinated groups (group 1 to 6) on day 69 with 
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Figure 1. The antibody response of all treatment groups tested over time by IDEXX 
ELIS A. The positive responses were determined at s/p ratio of 0.4 or higher. 
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the antibody titers ranging from 4 to 32. The percentage of pigs showing cross-neutralizing 
antibodies ranged from 20% in group 4 to 100% in groups 1 and 2. Strict negative control 
pigs (group 9) did not show neutralizing antibodies to either strain of virus throughout the 
study. 
3.3 IFNy responses 
The expression of IFNy was determined in PBMC cultured with live vaccine strain of 
PRRSV for 5 days and measured by four-color flow cytometry. In all live cells, the 
background IFNy expression in unstimulated and mock control cells was less than 5% 
throughout the study. Low levels of IFNy responses (<1% IFNy+ cells after background 
subtraction) were detected in all groups on day 28 post vaccination and no significant 
differences among the 9 groups were observed (data not shown). Increased IFNy expression 
was seen on day 42 and 55 post vaccination. MLV-vaccinated groups had significantly 
higher %IFNy+ cells than ORF5 peptide/CT and control groups (Fig. 2). Pigs vaccinated 
with MLV vaccine and IL-12 had the highest %IFNy+ cells, followed by pigs vaccinated with 
MLV vaccine and poly-ICLC or mixed ORF5 peptides, respectively. ORF5 peptide/CT-
administered and control pigs had low %IFNy+ cells. The MFIs of IFNy of MLV-vaccinated 
groups were also significantly higher than that of ORF5 peptide/CT and control groups (Fig. 
2). 
The %IFNy+ cells of each T-cell subset were compared to the same subset of the strict 
control group (group 9) (Fig. 3). CD4"CD8+yô" subset was the only T-cell subset of group 1 
(MLV vaccine alone) that showed significantly higher %IFNy+ cells than that of group 9. T-
cell subsets in pigs vaccinated with MLV vaccine and mixed ORF5 peptides 
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Figure 2. IFNy response of all live cells. PBMCs were incubated with culture media 
(unstimulated control), supernatant from uninfected MARC-145 cells (mock control), ConA 
plus PMA and ionomycin (positive control), and vaccine strain ofPRRSV (antigen-
stimulated). Shown are mean ± SEM of %IFNy+ cells and MFI of IFNy4" cells averaged from 
day 42 and 55 post vaccination. The letters a and b indicate groups that were significantly 
different from group 9 and group 1, respectively (p<0.05). See Table 1 for treatment group 
designation. 
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Figure 3. IFNy response by T-cell subsets. PBMCs were stained for 3 major porcine T-
cell markers (CD4, CDS, and y5 TCR) and intracellular IFNy after in vitro restimulation with 
vaccine virus. Shown are mean ± SEM of %IFNy+ cells averaged from day 42 and 55 post 
vaccination. The letters a, b, and c indicate groups that were significantly different from 
group 9, group 1, and both group 9 and 1, respectively (p<0.05). See Table 1 for treatment 
group designation. 
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and all but the CD4~CD8~yô+ T-cell subset for the MLV vaccine and IL-12-treated pigs had 
significantly higher %IFNy+ cells than that of control group. Pigs vaccinated with MLV 
vaccine and ET had significantly higher %IFNy+ cells than group 9 in CD4+CD8"y5" and 
CD4"CD8+yô"subsets, while pigs vaccinated with MLV vaccine and IFNa had significantly 
higher %IFNy+ cells than group 9 only in CD4+CD8"yô" subset. The non-T cells (CD4"CD8" 
yô") had higher %IFNy+ cells compared to group 9 for all MLV -vaccinated groups except 
MLV vaccine with IFNa group. 
To test further for the effect of vaccine adjuvants in contributing to an increase in 
IFNy response, the %IFNy+ cells of all groups were compared to group 1 (MLV vaccine 
alone). Only MLV vaccine plus mixed ORF5 peptides or IL-12 showed significantly higher 
%IFNy+ cells than MLV vaccine alone. The increased responses were seen in CD4"CD8+y6+ 
and CD4"CD8"yô+ T-cell subsets of MLV vaccine plus mixed ORF5 peptides (group 3), and 
CD4+CD8+yô" and CD4"CD8+yô+ T-cell subsets of MLV vaccine plus IL-12 (group 6). 
3.4 CD25 responses 
Fresh PBMCs had very low %CD25+ cells (<1%) for all treatment groups throughout 
the study (data not shown). PBMCs cultured for 5 days with live PRRSV had higher 
%CD25+ cells than fresh PBMCs, but the high %CD25+ cells were also seen in unstimulated 
cells and mock control. The high background of %CD25+ cells was seen consistently in 
every time point. To represent the actual antigen-specific CD25 responses, we employed the 
CD25EI as described by Sandbulte and Roth (2002). CD25EI of all groups were close to 1 at 
every time point, suggesting that no antigen-specific CD25 response occurred (data not 
shown). 
CD25EI of T-cell subsets are illustrated in Fig. 4. The CD25EI of every group in 
each subset was close to 1, and thus there was no significant difference of mean CD25EI 
among 9 groups in most T-cell subsets. CD4"CD8+yô+ and non-T cells (CD4"CD8~y8~) were 
the only subsets that showed mean CD25EI difference. The significant difference was seen 
in MLV-vaccinated group receiving IFNa, where mean CD25EI was higher than that of both 
group 1 (MLV vaccine alone) and group 9 (strict negative control). CD25EI of CD4" 
CD8+yô+ T-cell subset of MLV-vaccinated group receiving IL-12 was significantly higher 
than corresponding value in group 9. The low CD25 response in T cells stimulated with 
recall antigens raised the question of whether T cells expressing IFNy co-expressed surface 
CD25. To test this, a group-independent correlation analysis between %IFNy+ and CD25EI 
of every subset from individual pigs (n=88) was performed. The results consistently showed 
no significant correlation between IFNy expression and CD25EI in any subset of T cells 
except CD4+CD8+y8" subset (with p=0.05) (Table 3). 
3.5 Lung lesions and viremia 
After virus challenge, the challenge control pigs (group 8) developed severe lung 
lesions with a mean 35% lung damage (Fig. 5a). The ORF5 peptide/CT pigs (group 7) 
developed a comparable percent of lung damage as challenge control pigs, while MLV-
vaccinated pigs (groups 1 to 6) had reduced mean % lung lesions. However, the only 
significant reduction of lung lesions was seen in MLV-vaccinated pigs receiving ET or 
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Figure 4. CD25 response by T-cell subsets. PBMCs were stained for 3 major porcine 
T-cell markers (CD4, CD 8, and yô TCR) and surface CD25 after in vitro restimulation with 
vaccine virus. Shown are mean ± SEM of CD25EI averaged from day 42 and 55 post 
vaccination. The letters a, b, and c indicate groups that were significantly different from 
group 9, group 1, and both group 9 and 1, respectively (p<0.05). See Table 1 for treatment 
group designation. 
Table 3. Correlation coefficients obtained from group-independent correlation analysis 
between %IFNy+ cells collected from day 42 and 55 post vaccination and CD25EI obtained 
from the same days (n=88), lung lesion scores (n=76), or viremia (n=76). The same analysis 
was done between CD25EI and lung lesion scores (n=76), or viremia (n=76). 
CD25EI Lung lesion scores Viremia 
%IFNy+ 
All live cells -0.12 -0.34" -0.54** 
a|3 T cells 
CD4+CD8"yô" 0.23 -0.16 -0.28* 
CD4+CD8+y5" 0.25* -0.22* -0.25* 
CD4"CD8+y5" -0.10 -0.45** -0.46** 
yô T cells 
CD4"CD8+yô+ -0.01 -0.25* -0.27* 
CD4"CD8"yô+ -0.16 -0.07 -0.13 
Non-T cells 
CD4"CD8"yô" -0.05 -0.44** -0.46** 
CD25EI 
All live cells - 0.04 0.18 
a(3 T cells 
CD4+CD8"yô" - 0.04 0.12 
CD4+CD8+yô" - -0.11 -0.07 
CD4"CD8+yô" - 0.04 0.19 
yô T cells 
CD4"CD8+yô+ - -0.04 0.05 
CD4"CD8"yô+ - -0.08 -0.03 
Non-T cells 
CD4"CD8"yô" - 0.21 0.001 
* p<0.05, ** p<0.01 
IL-12 when compared to the challenge control pigs. The reduced lung lesions of both ET 
and IL-12 groups were not significantly different from that of MLV vaccine alone (group 1) 
(pX).05). 
In addition to lung lesions, the presence and level of virus in serum were monitored 
and quantified. Viremia was detected in every group at 4 days after challenge and persisted 
for 7 days in MLV-vaccinated groups, and 14 days in ORE5 peptide/CT and challenge 
control groups (data not shown). MLV -vaccinated pigs had significantly reduced percentage 
of viremia (Fig. 5b) and number of virus copies (except MLV vaccine with mixed ORF5 
peptides) (Fig. 5c) than ORF5 peptide/CT and challenge control pigs. MLV-vaccinated pigs 
receiving poly-ICLC had the lowest percentage of viremia, while MLV vaccine alone or with 
IL-12 pigs had the lowest number of virus copies. However, none of these were significantly 
different (P >0.05) from MLV vaccine alone. 
3.6 Correlation of immune responses with lung lesions and viremia 
A group-independent correlation analysis between %IFNy+ or CD25EI and lung 
lesion scores or virus copies was performed (Table 3). Robust inverse correlations between 
%IFNy+ cells and lung lesion scores or number of virus copies were detected. Further 
analysis by subsets between %IFNy+ and the two parameters revealed that the correlations 
between %IFNy+ and lung lesion scores were robust in CD4"CD8+yô" and CD4"CD8"yô" 
subsets, and to a lesser extent, CD4"CD8+yô+ and CD4+CD8+y8" subsets. Inverse correlation 
between %IFNy+ cells and the number of virus copies was seen in all subsets except CD4" 
CD8~yô+. The strongest correlations were also found in CD4"CD8+yô" and CD4"CD8"y5" 
subsets, and to a lesser extent, CD4+CD8"yô", CD4"CD8+yô+, and CD4+CD8+yô", respectively. 
The expression of CD25 did not correlate with the reduction of lung lesion scores or 
viremia (Table 3). Analysis by subsets also revealed that T cells expressing CD25 did not 
significantly correlate with either parameter. 
A similar correlation analysis between ELIS A s/p ratio on day 55 and lung lesion 
scores or number of virus copies (n=76) was performed. A strong inverse correlation 
between s/p ratio and the two parameters was found (p<0.01) (Table 4). 
3.7 Immunity index and protection 
Both CMI (represented by %IFNy+) and HMI (represented by ELIS A s/p ratio) were 
significantly correlated with the reduction of lung lesion scores and number of virus copies. 
However, there were pigs with very low s/p ratios and pigs with very low %IFNy+ that were 
protected from challenge based on lung scores or viremia (Fig. 7). This raised the possibility 
that the pigs with low s/p ratios may have been protected by a high %IFNy+ response and that 
pigs with a low %EFNy+ response may have been protected by a high antibody response. To 
test this possibility, we calculated an immunity index which approximately equally weighted 
the HMI and CMI responses. To collectively summarize the protection provided by CMI and 
HMI, we combined the two aspects of immune response and presented the result as immunity 
index. The immunity index of all MLV -vaccinated groups was significantly higher than that 
of ORF5 peptide/CT and control groups in every T-cell subset (Fig. 6). A significant inverse 
correlation between immunity index and lung lesion scores or number of virus copies was 
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Table 4. Correlation coefficients obtained from group-independent correlation analysis 
between ELIS A s/p ratio from day 55 post vaccination or immunity index and lung lesion 
scores or viremia (n=76). 
Lung lesion scores Viremia 
ELISA s/p ratio -0.50" -0.42" 
Immunity index 
All live cells -0.51** -0.53** 
a|3 T cells 
CD4+CD8yô" -0.47** -0.45** 
CD4+CD8+yô" -0.50** -0.46** 
CD4"CD8+yô~ -0.51** -0.54** 
yô T cells 
CD4"CD8+yô+ -0.50** -0.46** 
CD4"CD8"yô+ -0.43** -0.42** 
Non-T cells 
CD4"CD8~yô" -0.52" -0.54** 
** p<0.01 
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Figure 6. Mean ± SEM of immunity index by subsets. Immunity index was derived 
from the summation of HMI (represented by ELIS A s/p ratio on day 55 multiplied by 10) and 
CMI responses (represented by %IFNy+ T cells by subsets averaged from day 42 and 55). 
The letters a and b indicate groups that were significantly different from group 9 and group 1, 
respectively (p<0.05). See Table 1 for treatment group designation. 
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observed (Table 4). The immunity index did not correlate any more strongly with protection 
than either the s/p ratio or the %IFNy+ response (Tables 3 and 4). There were individual pigs 
with a low immunity index (ie. no measureable antibody or IFNy production) that were still 
protected from challenge based on lung lesion score (Fig. 7). However, all pigs with an 
immunity index below 15 were viremic 14 days after challenge (Fig. 7). 
3.8 Correlation of lung lesion scores with level of viremia 
A positive correlation existed between lung lesion scores and levels of viremia 14 
days after challenge (Fig. 8). However, many individual pigs had high levels of viremia and 
essentially no lung lesions while other pigs had high lung lesion scores with no detectable 
viremia 14 days after challenge (Fig. 8). 
4. Discussion 
Several vaccine adjuvants for the MLV PRRSV vaccine and a vaccine antigen ORF5 
peptide/CT were studied for their potential to increase HMI and CMI responses as well as to 
protect pigs from virulent PRRSV challenge. CT has been reported to induce neutralizing 
(anti-GP5) antibodies after MLV PRRSV vaccination (Foss et al., 2002). Its adjuvant effect 
was further tested in this study with ORF5 peptide antigens. 
After vaccination, antibody responses detected by DDEXX ELISA were seen in all 
MLV-vaccinated pigs by day 28 post vaccination but were not detected in ORF5 peptide/CT 
pigs until 2 weeks after challenge (day 69). Previous studies reported that 
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Figure 8. Scatter plot and group-independent correlation analysis between lung lesion 
scores and logio viremia at day 14 after challenge. Correlation coefficient (r) represents a 
positive correlation between lung lesion scores and logio viremia (p<0.01). 
IDEXX ELISA preferentially captures antibodies specific to the nucleocapsid protein of the 
virus which is encoded by ORF7 (Yoon et al., 1995; Kwang et al., 1999; Foss et al., 2002). 
Therefore, the pigs administered ORF5 peptide/CT may have developed anti-GP5 antibodies 
but the antibodies were not detected by IDEXX ELISA. The positive ELISA responses of 
ORF5 peptide/CT group post challenge were likely induced by the challenge virus rather 
than the ORF5 peptides themselves. 
Pigs from all groups failed to develop neutralizing antibodies prior to virus challenge. 
After challenge, however, only pigs vaccinated with MLV (with or without other adjuvants) 
developed neutralizing antibodies, whereas ORF5 peptide/CT pigs did not. This suggests 
that MLV vaccination contributed to rapid induction of neutralizing antibody to the challenge 
virus. The percentage of pigs showing neutralizing antibodies to MN-184 and SDSU-73 
were highest in pigs vaccinated with MLV vaccine alone or combined with ET, suggesting 
that vaccine adjuvants did not contribute to enhancing the production of neutralizing 
antibodies. The lack of neutralizing antibody production in ORF5 peptide/CT group 
correlated with the high lung lesion scores and high viremia observed in pigs in this group. 
The magnitude of both clinical parameters were similar to those for the challenge control 
pigs. This suggests that administration with ORF5 peptide/CT did not induce protective 
immunity against challenge virus. The absence of neutralizing antibody production may be 
due to the lack of post translational modification of chemically-synthesized peptides. Correct 
glycosylation and post-translational modification of the GP5 may be required for successful 
induction of neutralizing antibodies (Pirzadeh and Dea, 1998). The activity of CT after 
chemical conjugation with ORF5 peptides was not determined. A loss of CT activity could 
contribute to poor neutralizing antibody response to ORF5 peptides. Another possible 
explanation may be that the ORF5 peptides used in this study were derived from virus 
isolates that were heterologous to the challenge virus (MN-184), therefore, antibodies 
induced by those peptides may inefficiently protect against the heterologous virus challenge. 
Antibodies detected by IDEXX ELISA were previously reported to not have 
neutralizing activity (Yoon et al., 1995; Foss et al., 2002). Nonetheless, the ELISA s/p ratio 
prior to virus challenge showed a strong inverse correlation with lung lesions and level of 
viremia. Since neutralizing antibodies were not detected prior to virus challenge, antibodies 
to PRRSV detected by IDEXX ELISA may play a protective role other than virus 
neutralization. This may be through complement activation, opsonization for phagocytosis, 
or antibody-dependent cell-mediated cytotoxicity. Neutralizing antibody responses in MLV-
vaccinated pigs which developed after virus challenge may also have contributed to 
protection. 
CMI responses were evaluated by up regulation of surface expression of CD25 and 
by intracellular expression of IFNy by T cells in response to PRRSV recall antigen. 
Significant up regulation of surface expression of CD25 was rarely seen in T-cell subsets 
after stimulation with recall antigens in vitro. CD4"CD8+yô+ T cells and non-T cells (CD4" 
CDS'yô") of the MLV plus IFNa group were the only subsets that showed a significant 
difference from the non-vaccinated control group (Fig. 4). In addition, up regulation of 
CD25 did not significantly correlate with either lung lesion score or level of viremia (Table 
3). While the up regulation of CD25 expression was minor, the intracellular expression of 
IFNy was significantly (p<0.05) increased in response to recall antigen in all T-cell subsets 
for at least some of the vaccinated groups as compared to the non-vaccinated group (Fig. 3). 
In addition, increased expression of IFNy was significantly (p<0.05) inversely correlated 
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with lung lesion score and level of viremia. This finding indicates a lack of correlation 
between CD25 and IFNy expression in pigs in response to PRRSV recall antigen. CD25 
expression is an early event of T-cell proliferation and is used to detect activated porcine T 
cells (Saalmuller et al., 1994). CD25 should have been expressed prior to the expression of 
IFNy. Similar results were observed in a pseudorabies virus model in which IFNy production 
did not correlate with lymphocyte proliferation (Zuckermann et al., 1998). The low level of 
CD25 up regulation in response to PRRSV recall antigen may contribute to a weak CMI 
response to PRRSV. 
Increased IFNy responses were detected on day 42 and 55 post vaccination in all 
MLV-vaccinated groups for at least some lymphocyte subsets. This is later after vaccination 
than a previous study by Foss et al (2002), using an ELISPOT assay which detected IFNy 
production as early as 14 days post MLV PRRSV vaccination. The %IFNy+ cells detected in 
the present study were higher than that observed by ELISPOT assay at 42 days post 
vaccination. The different results may be explained by differences in the assays used, the 
recall antigens used, and/or the duration of incubation periods. In this study, live vaccine 
viruses were used at low titers to stimulate antigen-specific T cells and the incubation period 
was five days, while in the ELISPOT assay, heat-inactivated viruses were used at high titers 
and the incubation period was much shorter (usually less than 24 hours). During the longer 
incubation period, cytokines produced by antigen-specific T cells may induce proliferation of 
antigen-specific T cells and IFNy secretion in bystander cells (as detected in CD4"CD8"yô" 
subset). IFNy secreted by proliferating T cell and bystander cell populations may contribute 
to higher %IFNy+ cells. 
A significant IFNy response to recall vaccine antigens was detected in the CD4" 
CD8+y8" T cell subset of pigs which were vaccinated with MLV vaccine alone, suggesting 
that MLV vaccine had primed this subset (Fig. 3). CD4~CD8+y8" T cells are classified as 
cytotoxic T cells in pigs (Pauly et al., 1995; Yang and Parkhouse, 1997). IFNy expression by 
these cells significantly correlates with the reduction of lung lesions and level of viremia 
(Table 3). 
Porcine IL-12 (group 6) and mixed ORF5 peptides (group 3) when used as adjuvants 
with the MLV vaccine significantly increased the IFNy response to recall antigen as 
compared to MLV vaccine alone (Fig. 3). Booster with mixed ORF5 peptides significantly 
increased IFNy response in CD4"CD8+y8+ and CD4"CD8"y8+ subsets, whereas co­
administration of MLV vaccine with IL-12 significantly increased IFNy response in CD4" 
CDS y8^ and CD4+CD8+y8" subsets. CD4"CD8+y8+ and CD4"CD8~y8+ subsets are classified 
as non MHC-restricted, with natural killer activity in the CD4"CD8+yS+ subset (Pauly et al., 
1 9 9 6 ;  Y a n g  a n d  P a r k h o u s e . ,  1 9 9 6 ) .  T h e  C D 4 + C D 8 + y 8 ~  c e l l s  a r e  c h a r a c t e r i z e d  a s  m e m o r y  T h  
cells with MHC class II restriction (Summerfield et al., 1996; Zuckermann and Husmann, 
1996; Saalmuller et al., 2002). IFNy expressed by these subsets correlates significantly with 
clinical protection. The mechanism of enhancement of the IFNy recall response by these 
subsets by mixed ORF5 peptides and porcine IL-12 is not clearly understood. The ORF5 
peptides have previously been shown to enhance HMI rather than CMI (Pirzadeh and Dea, 
1997). IL-12, on the other hand, was shown to induce IFNy expression when used as an 
adjuvant for an inactivated pseudorabies virus vaccine (review in Zuckermann et al., 1999) or 
the MLV PRRSV vaccine (Foss et al., 2002). However, the responsive T-cell subsets were 
not determined in those studies. The dosage of IL-12 used in this study was 4 |ig (single 
dose on day 1 post vaccination), while a previous study by Foss et al (2002) administered a 
total of 60 \ig on day 2, 4, and 7 after vaccination. The results reported here indicate that a 
lower dose of IL-12 was sufficiently potent to induce an increased IFNy response to MLV 
PRRSV vaccine. Although mixed ORF5 peptides and porcine IL-12 when used as adjuvants 
significantly enhanced IFNy responses to MLV vaccine, there was no statistically significant 
corresponding improvement in either lung lesion scores or level of viremia (Fig. 5). 
ELISA s/p ratio, IFNy production by CD4"CD8+yô" T cells and IFNy production by 
non-T cells (Tables 3 and 4) strongly correlated with protection from viremia and 
development of lung lesion scores. The correlation coefficient was less than -0.40 in each 
case and was highly significant (P<0.01) (Tables 3 and 4). This implies that both the 
antibody response and production of IFNy contribute to protection. In order to determine if 
the combination of ELISA s/p ratio and IFNy production by lymphocyte subsets might be a 
better predictor of resistance to challenge we combined these two parameters into an 
immunity index which approximately equally weighted the ELISA s/p ratio and IFNy 
production by each lymphocyte subset. The immunity index for each cell subset for each pig 
was then analyzed for correlation with viremia and lung lesion scores. The immunity index 
did not correlate any more strongly with protection from viremia or lung lesion scores than 
did the ELISA s/p ratio or IFNy production alone. Several pigs with low immunity index 
also had low lung lesion scores, however, all pigs with immunity index <15 had relatively 
high viremia (Fig. 7). 
In conclusion, pigs receiving MLV vaccine with or without vaccine adjuvants had 
higher ELISA antibody and IFNy recall responses prior to virus challenge and lower lung 
lesion scores and levels of viremia after challenge than non-vaccinated pigs. Both ELISA s/p 
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ratio and IFNy expression prior to virus challenge significantly correlated with reduced lung 
lesion scores and levels of viremia. This suggests that both immune parameters can be used 
to predict clinical protection. 
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Chapter 4. Effects of porcine reproductive and respiratory syndrome virus 
virulence and antigen-presenting cells on T cell activation 
and antiviral cytokine production 
A paper submitted to Viral Immunology 
Wasin Charerntantanakul, Ratree Piatt, James A. Roth 
ABSTRACT 
The ability of porcine reproductive and respiratory syndrome virus (PRRS V) to 
suppress T cell expression of CD25 (alpha chain of interleukin (IL)-2 receptor), interferon 
gamma (IFNy), and tumor necrosis factor alpha (TNFa) was determined by flow cytometry 
in naïve porcine T cells in response to mitogen (concanavalin A) and cytokine inducers 
(phorbol 12-myristate 13-acetate plus ionomycin (PMA/I)). Four PRRSV isolates of varying 
clinical virulence and three different types of porcine myeloid antigen-presenting cells (APC) 
were used. T cells cultured with monocytes infected with virulent PRRSV (VR-2385, 
SDSU-73, VR-2332), but not with vaccine strain (Ingelvac® PRRS MLV, Boehringer 
Ingelheim Vetmedica), demonstrated significantly reduced %CD25+ and %IFNy+ when 
compared to T cells incubated with uninoculated monocyte cultures (p<0.05). T cells 
cultured with monocytes infected with all four PRRSV isolates demonstrated significantly 
reduced %TNFa+ (p<0.05). The significant reduction of %CD25+, %rFNy+, and %TNFa+ 
was not detected in T cells cultured with monocyte-derived macrophages (MDM) and 
immature monocyte-derived dendritic cells (MDC) infected with any PRRSV isolates. Heat-
inactivated PRRSV did not induce significantly reduced T cell responses in any APC 
cultures. The reduction of T cell response in monocyte cultures was not due to PRRSV-
induced T cell death. Gene expression of IL-10 detected by semi-quantitative reverse 
transcriptase PGR was significantly increased in virulent PRRSV-infected monocyte cultures 
after PMA/I, but not con A stimulation, compared to IL-10 gene expression from 
uninoculated monocyte cultures (p<0.05). Increased IL-10 gene expression contributed to 
significantly reduced %IFNy+ and %TNFa+, but not %CD25+, as determined by an IL-10 
neutralization assay. This study reports that PRRSV has an ability to suppress T cell 
response. The suppressive ability of PRRSV associates with virus virulence and is mediated 
by virus-infected monocytes, but not by virus-infected MDM and immature MDC. 
INTRODUCTION 
Porcine reproductive and respiratory syndrome virus (PRRSV) is a positive-sense, single-
stranded enveloped RNA virus of the family Arteriviridae (36). The virus causes respiratory 
disease in pigs of all ages and reproductive losses in breeding age swine (36). 
Several lines of evidence suggest that PRRSV may possess immunosuppressive 
properties. Field investigations revealed that pigs infected with PRRSV had increased 
incidence of secondary infections with Streptococcus suis, Hemophilus parasuis, 
Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae, Salmonella spp., and swine 
influenza virus, compared to PRRSV-free pigs (15,48,70). Pigs infected with PRRSV and S. 
suis developed more severe clinical disease and pathological lesion caused by S. suis than 
pigs infected with S. suis alone (63). PRRSV infects monocytes, macrophages, and dendritic 
cells which are antigen-presenting cells (APC) of pigs (10,20,22,38,60,62,63,66). 
Macrophages infected with PRRSV demonstrate reduced phagocytic ability, microbial 
killing, production of reactive oxygen species ie. superoxide anion (o2") and hydrogen 
peroxide (h2o2), and production of antiviral cytokines ie. interferon alpha (IFNa) and tumor-
necrosis factor alpha (TNFa) compared to uninfected macrophages (2,12,30,62). PRRSV-
infected macrophages as well as uninfected bystander lymphocytes may be induced to 
undergo apoptosis (53,57). Humoral and cell-mediated immune (CMI) responses to PRRSV 
are poor, compared to those to other swine viral pathogens eg. pseudorabies virus and swine 
influenza virus (61). Specific antibodies to PRRSV detected by IDEXX ELIS A appeared 
around 2 weeks after infection (17,34,69). Neutralizing antibodies to PRRSV appeared 
around 4 weeks after infection (69). T cell proliferation and IFNy secretion by peripheral 
blood mononuclear cells (PBMC) in recall response to PRRSV appeared around 3-8 weeks 
after infection (5,8,11,17,29,33,34,50). PRRSV-primed T cells did not up-regulate CD25 
(alpha chain of interleukin (IL)-2 receptor) expression after re-stimulation in vitro with recall 
PRRSV (11). CD25 expression is reportedly up-regulated in activated porcine T cells after 
stimulation with either recall antigen or mitogen (23,52,56). 
The objective of this study was to determine the ability of PRRSV to suppress T cell 
response. Expression of CD25, EFNy, and TNFa by naïve T cells were evaluated after T cells 
were cultured with PRRSV-infected monocyte, monocyte-derived macrophages (MDM), and 
immature monocyte-derived dendritic cells (MDC) and stimulated with concanavalin A (con 
A) for CD25 up-regulation and phorbol 12-myristate 13-acetate plus ionomycin (PMA/I) for 
IFNy and TNFa up-regulation. PRRSV of varying clinical virulence were used. The effect 
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of PRRSV virulence as well as PRRSV-infected APC on T cells has not been determined. 
The effects of PRRSV virulence have been demonstrated in the disease severity and humoral 
immune response (19-21,26,65). Virulent PRRSV induces more severe respiratory disease 
and reproductive failure, poorer growth performance, and higher mortality rate than low 
virulent virus (19-21,26,65). Antibody response to virulent PRRSV appears more rapidly 
and has higher ELISA s/p ratio than antibody response to low virulent PRRSV (26,65). 
This study reported that PRRSV has the ability to suppress T cell response which is 
determined by significantly reduced CD25, IFNy, and TNFa expression in response to con A 
and PMA/I. The suppressive effect associates with virus virulence and is mediated by 
monocytes, but not by MDM and immature MDC. 
MATERIALS AND METHODS 
Animals and viruses. Three 10-week old PRRSV-seronegative pigs were used. The 
pigs were housed at the laboratory animal facility, College of Veterinary Medicine, Iowa 
State University (ISU). The animal experiment was approved by the ISU animal care and 
use committee. 
Four PRRSV isolates with known clinical virulence were used (42,47). The high virulent 
strains, American Type Culture Collection (ATCC) PRRSV isolate VR-2385 (Dr. Patrick 
Halbur, ISU) and isolate SDSU-73 (Dr. Michael Roof, Boehringer Ingelheim Vetmedica, Inc. 
(BIVI), Ames, LA), were recovered from bronchoalveolar lavage (BAL) fluid of 
experimentally infected pigs. The moderate virulent ATCC PRRSV isolate VR-2332 was 
from stock virus at passage seven in MARC-145 cells (Dr. Kenneth Piatt, ISU). The PRRS 
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MLV was from commercial Ingelvac® PRRS MLV vaccine (BIVI, St. Joseph, MO). All 
viruses were subsequently propagated in MARC-145 cells grown in DMEM4-1" (DMEM (Life 
Technologies, Gaithersburg, MD), 10% heat-inactivated fetal bovine serum (FBS; Atlanta 
biologicals, Norcross, GA), and 1% tissue culture penicillin (10,000 IU/ml)/streptomycin 
(10,000 ng/ml) (Mediatech, Herndon, VA)) to the titer of 106 tissue culture infectious dose 
50% (TCIL>5o)/ml. Virus titration was performed by indirect immunofluorescent assay (IFA) 
using mouse anti-PRRSV monoclonal antibodies (mAbs) (clone 15E; Dr. Kenneth Piatt, 
ISU), followed by fluorescein isothiocyanate (FITC)-conjugated sheep anti-mouse IgG 
antibodies (Sigma, St. Louis, MO). PRRSV isolates VR-2385, SDSU-73, VR-2332, and 
MLV were used at cell culture passage five, five, nine, and two, respectively. Mock antigens 
were prepared in the same fashion from uninfected MARC-145 cells. Heat inactivation of 
virus was performed at 56°C for 8 hours. Complete virus inactivation was confirmed by 
negative IF A test in inoculated MARC-145 cells. 
Antibodies. Mouse mAbs anti-porcine cell surface antigens were all from VMRD 
(Pullman, WA). They were anti-major histocompatibility complex (MHC) class II (clone 
H42A, isotype IgG2a), anti-swine workshop cluster 3a (SWC3a; swine myeloid marker) 
(clone 74-22-15a, isotype IgG2b), anti-CD3 (clone 8C8, isotype IgG2a), and FITC-
conjugated anti-8 chain of yô T cell receptor (TCR) (clone PGBL22A, isotype IgGl) Anti-
CD4 (clone 74-12-4, isotype IgG2b) and anti-CD8a (clone 76-2-11, isotype IgG2a) mAbs 
were produced in our laboratory by hybridomas from ATCC (Manassas, VA). Secondary 
antibodies included Alexa Fluor®647-conjugated goat anti-mouse IgG2a (y2a) (Molecular 
Probes, Eugene, OR), Tri-color®-conjugated goat anti-mouse IgG2b (y) (Caltag Laboratories, 
Burlingame, CA), and FITC-conjugated goat anti-mouse IgG2b (Southern Biotech, 
Birmingham, AL). 
Mouse mAbs anti-porcine activation marker CD25 (clone PGBL25A, isotype IgGl, 
VMRD, Pullman, WA) and anti-porcine TNFa (clone 4F4, isotype IgGl, Pierce 
biotechnology, Rockford, IL) were custom-conjugated with R-phycoerythrin (R-PE) by 
Chromaprobe Inc. (Maryland Heights, MO). The R-PE-conjugated anti-porcine IFNy (clone 
P2G10, isotype IgGl) mAb was from BD Pharmingen (San Diego, CA). Unconjugated 
mouse anti-swine IL-10 mAb (clone 945A4C437B1, isotype IgGlx, Bio source, Camarillo, 
CA) was used for IL-10 neutralization assay. The unconjugated anti-IFNy and anti-TNFa 
mAbs of the same clone were used for antibody blocking control in intracellular cytokine 
staining. All isotype control mAbs were from Southern Biotechnology Associates, Inc. 
(Birmingham, AL). 
Cell preparation. Isolation ofPBMC. Anti-coagulated blood were collected in 0.1 
volume of 2x acid-citrate-dextrose (0.15M sodium citrate, 0.076M citric acid monohydrate, 
0.287M dextrose) solution, diluted with equal volume of phosphate buffered saline (PBS) 
and layered onto lymphocyte separation medium (1.077 gm/ml, Mediatech, Herndon, VA), 
then centrifuged at 1,200 xg and 25°C for 30 minutes. PBMC were collected, washed once 
with PBS, and centrifuged at 270 xg and 4°C for 10 minutes. Contaminating red blood cells 
were lysed with 3 volumes of buffered water (0.15M sodium phosphate dibasic (Na^HPG^) 
and 0.15M potassium phosphate monobasic (kh2po4)) for 90 seconds and restored with 1.5 
volumes of 3x PBS. PBMC were resuspended in RPMI++ (RPMI-1640 with 25mM HEPES 
and L-glutamine (Life Technologies, Gaithersburg, MD), 10% heat-inactivated FBS (Atlanta 
biologicals, Norcross, GA), and 1% tissue culture penicillin (10,000 IU)/streptomycin 
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(10,000 ng/ml) (Mediatech, Herndon, VA)) or PBS++ (PBS, 0.25% heat-inactivated FBS, and 
0.025% sodium azide (NaNg) (Sigma, St. Louis, MO)). PBMC resuspended in RPMI++ were 
for preparation of APC, and PBMC resuspended in PBS" were for preparation of purified 
lymphocytes. PBMC were counted by automatic cell counter (Beckman coulter, Inc., 
Fullerton, CA) and their concentrations were adjusted to 107 cells/ml. 
Preparation of APC. One hundred (il of PBMC in RPMI^ (107 cells/ml) were placed into 
each well of a 96-well flat-bottom plate (BD Labware, Franklin Lakes, NJ) and incubated for 
4 hours at 37°C in humidified, 5% CO2 atmosphere. Non-adherent cells were removed and 
adherent cells were gently washed once with 150 gl pre-warmed (37°C) RPMI^ to obtain 
monocytes. Adherent monocytes were cultured continuously in the same incubation 
environment for another 7 days to obtain MDM and immature MDC. Monocytes to be 
derived to MDM were cultured in 300 jxl RPMI++, while monocytes to be immature MDC 
were cultured in 300 JJ.1 RPMI1"1" supplemented with recombinant human granulocyte-
macrophage colony-stimulating factor (rhuGM-CSF) at 20 ng/ml (eBioscience, San Diego, 
CA) and recombinant porcine IL-4 (rpoIL-4) at 40 ng/ml (Biosource, Camarillo, CA). Half 
of culture media (150 JJ.1) was removed and replaced with fresh media (with rhuGM-CSF and 
rpoIL-4 for immature MDC) every other day. Confirmation of monocyte, MDM, and 
immature MDC phenotype was made by flow cytometry, using a combination of anti-
SWC3a and anti-MHC class II mAbs (Fig. 1). 
Preparation of purified lymphocytes. PBMC in PBS + at 107 cells/ml were transferred to 
50 ml sterile polypropylene centrifuge tubes (Falcon®, BD, Franklin Lakes, NJ) and received 
10 (il of anti-SWC3a mAbs (1 mg/ml) per ml of cell suspension. They were then incubated 
at 4°C for 60 minutes with gentle tumbling motion, centrifuged at 270 xg (4°C, 10 minutes), 
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and washed twice with cold PBS"1™1". PBMC were then resuspended with Dynabeads® M450 
pan mouse IgG (Dynal Biotech, Brown Deer, WI) in PBS++ at the ratio recommended by the 
manufacturer. Cells were incubated at 4°C for 60 minutes with gentle tumbling motion, then 
transferred to sterile snap-cap 5 ml polystyrene round-bottom tubes (Falcon®, BD, Bedford, 
MA), and placed in a magnetic particle concentrator (Dynal A.S., Oslo, Norway) for 3 
minutes to deplete antibody-bound monocytes. The resulting cells were transferred to a new 
snap-cap tube and the monocyte depletion was repeated one more time. At the end of the 
monocyte depletion processes, the lymphocytes were washed with 10 volumes of PBS% 
centrifuged at 270 xg (4°C, 10 minutes), and cell pellets were resuspended in RPMI++ to 107 
cells/ml. The purified lymphocytes contained less than 1% monocytes (SWC3+) as 
determined by flow cytometry (data not shown). 
Cultures of cells. The culture plates containing adherent monocyte, MDM, and immature 
MDC were centrifuged at 270 xg (25°C, 1 minute) and the cells were gently washed once 
with 150 gl pre-warmed (37°C) RPMl". Each cell type was then received 100 (il of freshly 
purified lymphocytes in RPMI++ (107 cells/ml) from the same animal. After addition of 
lymphocytes, each APC culture then received 100 p.1 of either live PRRSV (106 TdD50/ml), 
heat-inactivated PRRSV (106 TCIDso/ml), mock antigen (to serve as negative control), or 
mock antigen (which was later stimulated with con A or PMA/I to serve as positive control). 
The ratio of lymphocytes added to monocyte, MDM, and immature MDC resembled the ratio 
of lymphocyte to monocyte in peripheral blood of pigs at the same age, approximately 10:1 
(55). The cultures were incubated at 37°C for 2 days in a humidified, 5% CO2 atmosphere. 
Infection of PRRSV in monocytes, MDM, and immature MDC was detected by IF A (mouse 
anti-PRRSV mAbs (clone 15E)) at day 2 of cell culture. At the end of day 2, one plate of 
each APC culture received 50 pi of con A (5 pg/ml final, Sigma, St. Louis, MO) in RPMI4^ 
in all wells except wells containing mock control. Two plates of each APC culture received 
50 pi of a combination of PMA (7 ng/ml final, Sigma, St. Louis, MO), ionomycin (430 ng/ml 
final, Sigma, St. Louis, MO), and GolgiStop® solution (Monensin, Pharmingen, San Diego, 
CA) at manufacturer recommended dilution in RPMI++ (PMA/I) in all wells except wells 
containing mock control. The plates that received con A were incubated for 2 more days for 
CD25 up-regulation, while the plates that received PMA/I were incubated for 12 more hours 
for IFNy and TNFa up-regulation. The concentration of con A and PMA/I and the 
stimulation period used were optimized to obtain significant up-regulation of CD25, IFNy, 
and TNFa expression on T cells with minimum T cell death (data not shown). 
Determination of cell viability. The viability of T cells from each APC culture as well as 
monocytes, MDM, and immature MDC from the same well was determined at day 2 and 
after con A (day 4) and PMA/I (day 2.5) stimulation. In all cultures, all cells were mixed 
gently with a micropipette and transferred correspondingly to 96-well round-bottom plates. 
Remaining adherent cells were harvested by placing culture plates on ice for 15 minutes, 
followed by addition of 10 pi of cold PBS plus 5mM EDTA (Sigma, St. Louis, MO) at pH 
8.0 and incubated on ice for 10 minutes. All cells were then processed as described in 
fluorescent antibody labeling and stained with a combination of anti-CD3 and anti-SWC3a 
mAbs at previously titrated optimum dilutions. One hundred pi of propidium iodide (PI; 100 
pg/ml final, Molecular Probes, Eugene, OR) was added to the fluorescent-labeled cells prior 
to flow cytometry. 
Reverse transcriptase (RT)-PCR. RNA extraction and reverse transcription. In all APC 
cultures, all cells before (day 2) and after con A (day 4) and PMA/I (day 2.5) stimulation 
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were harvested and transferred to 96-well round-bottom plates (BD Labware, Franklin Lakes, 
NJ), centrifuged at 270 xg (4°C, 1 minute), washed once with PBS, resuspended with 200 pi 
of RNAlater (Ambion Inc., Austin, TX), and stored at -20°C until RNA extraction. Total 
RNA was extracted, using the Nucleospin RNA II kit (BD Clonetech Laboratories Inc., 
Mountain View, CA) according to manufacturer's instructions. Contaminating DNA was 
eliminated by Dnase I provided with the kit. Total RNA was eluted in 40 pi of RNase-free 
water. Of which, 10 pi from each sample was assigned to reverse transcription, using 
Omniscript RT kit (Qiagen Inc., Valencia, CA), 0.5 pg random hexamers (Promega 
Corporation, Madison, WI), and 40 U ribonuclease inhibitor (RNaseOUT, Invitrogen 
Corporation, Carlsbad, CA). The reverse transcription was performed in the total reaction 
volume of 20 pi and at 37°C for 60 minutes, followed by heat inactivation at 93°C for 5 
minutes and rapid cooling to 4°C. 
PCR. Complementary DNA (cDNA) of samples before stimulation (day 2) was used as a 
template for multiplex PCR of porcine IL-2, IL-10, and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), according to the protocols described by Suradhat et al (58) with 
minor adjustment. cDNA of the samples after con A (day 4) and PMA/I (day 2.5) 
stimulation was used as a template for traditional PCR of single gene due to unequal 
expression of the 3 genes after stimulation which was not suitable for multiplex PCR 
conditions. All primer sequences were from Suradhat et al (58). 
Multiplex and traditional PCR were performed in a total reaction volume of 50 pi, 
consisting of 2 pi cDNA template, 10 mM dNTPs (Invitrogen Corporation, Carlsbad, CA), 
and 1 unit Taq DNA polymerase (Platinum® Taq DNA Polymerase High Fidelity, Invitrogen 
Corporation, Carlsbad, CA). The volume of primer mix for multiplex PCR was 6 pi (1 pi of 
each primer) and for traditional PCR was 2 pi (1 pi of each primer). The final concentration 
of the primers was 0.6 pM, 0.2 pM, and 0.05 pM for IL-2, IL-10, and GAPDH, respectively. 
The PCR condition was 'hot start' at 94°C for 2 minutes; denaturation at 94°C for 30s; 
annealing at 55°C for 45s; extension at 68°C for 45s, and final extension at 72°C for 5 
minutes with the total number of 33 cycles for multiplex PCR and 30 cycles for traditional 
PCR. The number of PCR cycles of multiplex and traditional PCR was optimized by 
performing different numbers of PCR cycle and selecting the cycle that none of the PCR 
products reached the plateau phase during PCR amplification (data not shown). 
Quantification of the PCR products. Gel electrophoresis of PCR products was performed 
on 2.5% agarose (Gibco BRL, Grand Island, NY) in TBE buffer (Fisher Scientific company, 
Pittsburgh, PA) with 0.5 pg/ml ethidium bromide. Images of PCR products on agarose gel 
were visualized by UV illuminator and captured by GeneSnap software (version 4.01.00, 
Spectronics Corporation, Westburg, NY). Densitometric analysis of the PCR products was 
performed using GeneTools software (version 3.00.22, Spectronics Corporation, Westburg, 
NY). The expressions of IL-2 and IL-10 genes before cell stimulation (day 2) were presented 
as percentage ratio of cytokine/GAPDH expression of the same animal. The gene 
expressions after con A (day 4) and PMA/I (day 2.5) stimulation were presented as number 
of fold increase, calculated from the division of percentage ratio of cytokine/GAPDH 
expression from stimulated cells by corresponding value from mock control cells of the same 
animal. 
IL-10 neutralization assay. IL-10 neutralization assay was performed to determine 
whether significantly increased IL-10 mRNA expression caused significantly reduced CD25, 
IFNy, and TNFa expression. The assay was performed only in monocyte culture since it was 
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the only culture among all three APC cultures that showed significantly increased IL-10 
mRNA expression as well as significantly reduced CD25, IFNy, and TNFa expression. 
Mouse anti-swine IL-10 mAb (clone 945A4C437B1, Bio source, Camarillo, CA) was used 
for IL-10 neutralization. 
Three plates each containing 48 wells of adherent monocytes were used. They were for 
CD25, IFNy, and TNFa staining. In each plate, monocytes received 100 pi of lymphocytes 
(107 cells/ml) which had received either anti-swine IL-10 mAb at 2.5 pi or 25 pi per 1 ml 
lymphocytes, mouse isotype control mAb (clone 15H6, Southern Biotech, Birmingham, AL) 
at 25 pi per 1 ml lymphocytes (isotype control), or RPMI++ (no antibody control). Following 
the addition of purified lymphocytes, each well then received 100 pi of either live PRRSV 
(106 TCIDso/ml) or mock antigens. All plates were incubated at 37°C for 2 days in a 
humidified, 5% CO2 atmosphere. At the end of day 2, the plate that was for CD25 staining 
received 50 pi of con A (5 pg/ml final) and the plates that were for IFNy and TNFa staining 
received 50 pi of PMA/I (7 ng/ml/430 ng/ml final) in RPMI^. Plate receiving con A was 
incubated for 2 more days for CD25 up-regulation, while plates receiving PMA/I were 
incubated for 12 more hours for IFNy and TNFa up-regulation. The final concentrations of 
the anti-swine IL-10 mAb in the total 250 pi culture were 1 and 10 pg/ml (manufacturer's 
recommendations), respectively. The final concentration of the mouse isotype control mAb 
was 10 pg/ml. 
Fluorescent antibody labeling. Primary mAb mixture comprised anti-SWC3a and anti-
MHC class II mAbs for differentiation of APC; anti-CD3 and anti-SWC3a mAbs for 
determination of cell viability; anti-CD3 (or mixture of anti-CD4, anti-CD8a, and FITC-
conjugated anti-8 chain of yô TCR mAbs) and R-PE-conjugated anti-CD25 mAbs for surface 
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CD25 staining; anti-CD3 mAb alone (or mixture of anti-CD4, anti-CD8a, and FITC-
conjugated anti-5 chain of yô TCR mAbs) for intracellular IFNy and TNFa staining. 
Secondary antibody mixture consisted of Alexa Fluor®647-conjugated goat anti-mouse 
IgG2a (y2a) and Tri-color®-conjugated goat anti-mouse IgG2b (y). For cell viability 
determination, FITC-conjugated goat anti-mouse IgG2b was used in place of Tri-color®-
conjugated goat anti-mouse IgG2b (y). All antibodies were used at previously titrated 
optimum dilutions. 
At the conclusion of the culture period, the culture plates were chilled on ice for 15 
minutes and the cells were mixed gently and transferred to 96-well round-bottom plates. The 
plates were centrifuged at 270 xg and 4°C for 1 minute and washed three times with 150 pi 
of PBS++. The pellets were incubated with 50 pi primary mAb mixture in the dark at 4°C for 
30 minutes, followed by three washes with PBS^. Fifty pi of secondary antibody mixture 
were added and the plates were incubated for 30 minutes at 4°C in the dark, washed twice 
with PBS++ and once with PBS, then fixed with 150 pi of 1% ultrapure formaldehyde 
(Polyscience, Warrington, PA) in PBS. 
For intracellular IFNy and TNFa staining, after washing off secondary antibody mixture, 
cells were fixed with 100 pi of BD Cytofix/Cytoperm solution (Pharmingen, San Diego, CA) 
for 30 minutes at 4°C in the dark, washed twice with 150 pi of BD Perm/Wash (Pharmingen, 
San Diego, CA), and received 50 pi of R-PE-conjugated anti-porcine IFNy or R-PE-
conjugated anti-porcine TNFa mAb in BD Perm/Wash solution at previously titrated 
optimum dilutions. Cells were incubated in the dark for 30 minutes at 4°C, followed by three 
washes with BD Perm/Wash solution and fixed with 150 pi of 1% ultrapure formaldehyde in 
PBS. 
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Single-color controls, secondary antibody controls, unstained cells, isotype controls, and 
unconjugated antibody blocking controls for IFNy and TNFa staining were performed. The 
blocking controls were incubated with unconjugated mouse anti-porcine IFNy mAb (clone 
P2G10, isotype IgGl, BD Pharmingen, San Diego, CA), or unconjugated mouse anti-porcine 
TNFa mAb (clone 4F4, isotype IgGl, Pierce biotechnology, Rockford, IL), followed by their 
corresponding R-PE-conjugated mAbs. The fixed cell suspensions from all stainings were 
transferred to 5 ml polystyrene round-bottom tubes (BD, Franklin Lakes, NJ) and stored at 
4°C until flow cytometric analysis. 
Flow cytometry. The flow cytometric analysis was performed by the flow cytometry 
facility at ISU on an Epics Altra cytometer (Beckman Coulter, Fullerton, CA) equipped with 
both krypton (488 nm) and helium-neon laser (633 nm). The FITC, R-PE, PI, and Tri-Color® 
dyes were excited by the same 488 nm krypton laser. Alexa Fluor®647 dye was excited by a 
spatially separated 633 nm helium-neon laser. A gated amplifier was used to differentiate 
Tri-Color® and Alexa Fluor®647 signals, which were detected by the same photomultiplier 
tube. 
Flow cytometry data were analyzed, using Flow Jo analysis software (version 4.6.2, Tree 
Star, Inc. San Carlos, CA). Analyses of APC differentiation and cell viability were 
performed on total cell populations. A histogram based on SWC3a and CD3 was applied to 
total cell population, followed by a histogram based on MHC class II and PI on SWC3+ 
population and PI on CD3+ population. The geometric mean fluorescent intensity (MFI) of 
MHC class II and percentage of PI+ cells of each cell type were collected. 
Analyses of CD25, IFNy, and TNFa expression in T cells were performed on live cell 
populations after gating out of doublet and dead events from total cell populations according 
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to forward- and side-scatter distribution. A histogram based on CD3 was applied to live cell 
population, followed by a histogram of CD25, IFNy, and TNFa on CD3+ population. For T 
cell subset analysis, a histogram based on yô TCR was applied to live cell population, 
followed by a histogram based on CD25, IFNy, and TNFa on yô+ population. Quadrant 
markers were set on CD4 versus CD 8 T cells on yô" population, generating 4 defined 
lymphocyte subsets containing CD4+CD8"yô", CD4+CD8+yô", CD4 CD8+yô", and CD4"CD8" 
yô". A non-T cell subset (CD4"CD8"yô") was not further analyzed. The remaining 3 T cell 
subsets were gated for their percentage of CD25+, IFNy+, or TNFa+ on a histogram based on 
CD25, EFNy, and TNFa, respectively. 
Statistical analysis. All statistical analyses were performed using the JMP5.1 software 
(SAS Institute Inc., Cary, NC). Mean difference of MFI of MHC class II expression among 
monocyte, MDM, and immature MDC was tested by one-way analysis of variance, followed 
by Tukey-Kramer HSD test for multiple mean comparisons. Mean differences of %CD25+, 
%EFNy+, %TNFa+, and %PI+ of T cells of the same APC culture were tested among 
treatments by Kruskal-Wallis test, followed by Dunnett's test using mean of positive control 
as a control group. The same statistical methods (Kruskal-Wallis test and Dunnett's test) 
were used for analysis of mean differences of %PI+, IL-2 mRNA, and IL-10 mRNA of 
monocyte, MDM, and immature MDC cultures. P<0.05 was set as statistically significant 
level throughout this study. 
RESULTS 
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Differentiation of porcine APC. Monocytes, MDM, and immature MDC were 
differentiated from one another by differential MHC class II expression (6,24,32). At the end 
of cell culture period (day 7), immature MDC had significantly higher MHC class II 
expression than monocyte and MDM, respectively (p<0.05) (Fig. 1). Monocytes had 
significantly higher MHC class II expression than MDM (p<0.05) (Fig. 1). 
Effect of PRRSV and APC on T cell responses. CD25 response. All three types of 
porcine myeloid APC were infected with all four PRRSV isolates after 2-day of co-
cultivation as determined by IF A. Naïve T cells incubated with monocytes infected with 
VR-2385, SDSU-73, and VR-2332 demonstrated significantly reduced %CD25+ when 
compared to those from positive controls (p<0.05) (Fig. 2). No significant reduction of 
%CD25+ was observed in T cells cultured with monocytes infected with PRRS MLV. T cells 
from MDM and immature MDC cultures infected with PRRSV of all isolates did not show 
significantly reduced %CD25+ (Fig. 2). Heat-inactivated PRRSV did not induce 
significantly reduced %CD25+ in T cells from any APC cultures (data not shown). Analysis 
by T cell subset revealed that significantly reduced %CD25+ in monocyte cultures occurred 
in all subsets of a(3 T cells (CD4+CD8"yô", CD4+CD8+yô", CD4"CD8+yô") and yô+ T cells (Fig. 
3). 
IFNy and TNFa responses. Naïve T cells from monocyte culture infected with VR-2385, 
SDSU-73, and VR-2332 demonstrated significantly reduced %IFNy+ and %TNFa+ when 
compared to those from positive controls (p<0.05) (Fig. 2). Significant reduction of 
%TNFa+ but not %IFNy+ was observed in T cells from monocyte cultures infected with 
PRRS MLV (p<0.05) (Fig. 2). T cells from MDM and immature MDC cultures infected 
with PRRSV of all isolates did not show significantly reduced %IFNy+ and %TNFa+ (Fig. 2). 
FIGURE 1. Histogram of geometric mean fluorescent intensity (MFI) of MHC class II expressed in monocyte (left), monocyte-
derived macrophage (MDM) (center), and immature monocyte-derived dendritic cell (MDC) (right). Monocytes were obtained by 
plate adherence of naive PBMC. MDM were derived from monocytes by continuous adherence for 7 days in RPMI++. Immature 
MDC were derived from monocytes by continuous adherence for 7 days in RPMI++ supplemented with rhuGM-CSF (20 ng/ml) 
and rpoIL-4 (40 ng/ml). Half of the culture media were removed and replaced with fresh media every other day. Grey-filled 
histogram represents isotype control. The number represents mean MFI ± standard error of mean (SEM). 
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Heat-inactivated PRRSV did not induce significantly reduced %IFNy+ and %TNFa+ in T 
cells from any APC cultures (data not shown). Analysis by T cell subset in monocyte 
cultures revealed that significantly reduced %IFNy+ occurred in CD4+CD8"y5" and CD4" 
CD8+yô" T cells and significantly reduced %TNFa+ occurred in CD4+CD8"yô", CD4+CD8+yô" 
, and CD4"CD8+yô" T cells (Fig. 3). 
Effect of PRRSV on viability of T cells and APC. No significant difference in %PI+ of 
T cells was detected in any APC culture between PRRSV-infected groups and controls. The 
results were consistent in both before and after cell stimulation. The mean %PI+ of T cells 
before the stimulation, after con A, and after PMA/I stimulation was approximately 30-40%, 
60-70%, and 45-55%, respectively, in all treatments of all APC cultures (data not shown). 
Significant increase in %PI+ was detected in monocytes, MDM, and immature MDC 
infected with PRRSV of all isolates (Fig. 4). After 2 days of infection, 40-60% of 
monocytes, 70-90% of MDM, and 40-60% of immature MDC were dead, whereas only about 
20% of corresponding APC in mock control were dead (Fig. 4). The %PI+ were increased in 
all types of APC after con A and PMA/I stimulation (Fig. 4). MDM always showed the 
highest %PI+ among 3 types of APC. Heat-inactivated PRRSV did not induce significantly 
increased %PI+ in any APC culture compared to that in corresponding controls either before 
or after con A and PMA/I stimulation (data not shown). 
Gene expression of IL-2 and IL-10. No significant differences in IL-2 and IL-10 mRNA 
expression were detected before con A and PMA/I stimulation in any APC culture between 
PRRSV-infected groups and mock controls (Fig. 5). Only MDM cultures infected with 
SDSU-73 showed significantly increased IL-2 mRNA expression compared to mock control 
(p<0.05)(Fig. 5). 
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FIGURE 5. Mean %IL-2 and %IL~10 gene expression of monocyte, MDM, and immature 
MDC cultures after inoculation with PRRSV for 2 days. RT-PCR was performed on total 
RNA extracted from each sample in each APC culture. Presented data were after 
normalization with GAPDH gene expression of the same animal. Error bar indicates SEM. 
* p<0.05. 
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Significant increase in IL-2 mRNA expression was detected in monocyte cultures infected 
with VR-2385, SDSU-73, and VR-2332, and in MDM cultures infected with SDSU-73 and 
VR-2332 after con A stimulation, compared to corresponding positive controls (p<0.05) (Fig. 
6). There was relatively high IL-2 mRNA expression in immature MDC cultures in PRRSV-
infected groups and controls compared to that in monocyte and MDM cultures (Fig. 6). No 
significant difference of IL-10 mRNA expression was detected between PRRS V-infected 
groups and positive controls in any APC culture after con A stimulation (Fig. 6). 
Significant difference of IL-2 mRNA expression was not detected between PRRSV-
infected groups and positive controls in any APC cultures after PMA/I stimulation (Fig. 7). 
The IL-2 mRNA expression was relatively high in immature MDC cultures compared to that 
in monocyte and MDM cultures in both PRRSV-infected groups and controls (Fig. 7). The 
IL-10 mRNA expression was significantly increased in monocyte cultures infected with VR-
2385, SDSU-73, and VR-2332 (p<0.05) (Fig. 7). No significant increase of IL-10 mRNA 
expression was observed in MDM and immature MDC cultures infected with any PRRSV 
isolates (Fig. 7). 
IL-10 neutralization. Significantly reduced %IFNy+ and %TNFa+ but not %CD25+ of T 
cells in monocyte cultures were inhibited in the presence of anti-swine IL-10 mAbs (Fig. 8). 
Significantly reduced %TNFa+ were completely inhibited in monocyte cultures infected with 
all PRRSV isolates at low mAb concentration (1 p.g/ml). Significantly reduced %IFNy+ in 
monocyte culture infected with SDSU-73 and VR-2332 were inhibited at low mAb 
concentration (1 j-ig/ml), whereas significantly reduced %IFNy+ in monocyte culture infected 
with VR-2385 was inhibited at high mAb concentration (10 ng/ml) (Fig. 8). 
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FIGURE 6. Mean fold increase of IL-2 and IL-10 gene expression in monocyte, MDM, 
and immature MDC cultures infected with PRRSV and stimulated with con A. All cultures 
were incubated with PRRSV for 2 days and con A stimulation for another 2 days prior to RT-
PCR analysis. Data were normalized with GAPDH gene expression of the same animal. 
Error bar indicates SEM. * p<0.05. 
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FIGURE 7. Mean fold increase of IL-2 and IL-10 gene expression in monocyte, MDM, 
and immature MDC cultures infected with PRRSV and stimulated with PMA/I. All cultures 
were incubated with PRRSV for 2 days and received PMA/I stimulation for another 12 hours 
prior to RT-PCR analysis. Data were normalized with GAPDH gene expression of the same 
animal. Error bar indicates SEM. * p<0.05. 
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DISCUSSION 
The ability of PRRSV to suppress T cell response was evaluated on CD25, IFNy, and 
TNFa expression on naïve T cells in response to con A and PMA/I, respectively. Four 
PRRSV isolates possessing varying clinical virulence and three different types of porcine 
myeloid APC were used to compare their effects on T cell response. Significant reductions 
of %CD25+ and %IFNy+ were detected only after virulent PRRSV infection, while 
significant reduction of %TNFa+ was detected after infection with all four PRRSV isolates, 
suggested the differential effects of PRRSV virulence on different immune parameters. All 
reductions were detected only in monocyte cultures, indicated the role of monocytes in T cell 
suppression after PRRSV infection. 
Significant up-regulation of CD25 molecules on porcine T cells has been reported in 
response to con A (56). The expression of CD25 molecules was followed by proliferation of 
porcine T cells (56). Significantly reduced CD25 expression after virulent PRRSV infection 
may result in inhibition of clonal expansion of PRRSV-specific T cells, resulting in delayed 
CMI response. CMI response to PRRSV determined by T cell proliferation in response to 
recall PRRSV in vitro was detected 4 weeks after infection, which was relatively delayed 
compared to T cell proliferative response to pseudorabies virus and swine influenza virus 
which appeared within 1 week after infection (8,29,61). 
An inductive effect of PMA/I on IFNy and TNFa expression by porcine T cells has been 
reported (1,46). IFNy and TNFa have been demonstrated to inhibit PRRSV replication 
(9,30,49). Significantly reduced IFNy and TNFa expression after virulent PRRSV infection 
may facilitate PRRSV replication, as demonstrated by significantly higher PRRSV titers in 
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the serum after virulent PRRSV infection than after low virulent PRRSV infection (26). 
Significantly reduced CD25 expression on T cells after virulent PRRSV infection may also 
inhibit clonal expansion of PRRSV-specific IFNy-producing T cells and PRRSV-specific 
TNFa-producing T cells. T cells producing IFNy in response to PRRSV appeared in 
peripheral blood 3-8 weeks after PRRSV infection (5,11,17,33,34,50). This is considerably 
delayed compared to 1 week after pseudorabies virus infection (61). The percentage of T 
cells producing TNFa were significantly reduced when determined directly from peripheral 
blood of PRRSV-infected pigs (1). 
Absence of significantly reduced CD25 and IFNy, but not TNFa expression after PRRS 
MLV infection suggests that the vaccine virus may possess T cell suppressive property of 
lesser degree than virulent virus. Previous study on CD25 expression in T cells of pigs 
vaccinated with PRRS MLV showed no CD25 up-regulation in PRRS MLV-primed T cells 
after re-stimulation in vitro with recall MLV antigens (11). The ability of PRRS MLV to 
suppress TNFa expression may facilitate virus replication and thereby viremia of PRRS 
MLV after vaccination (17,35,40). 
Effects of monocytes, MDM, and immature MDC on T cells in response to PRRSV have 
not been determined. Porcine monocytes, macrophages, and dendritic cells have been 
reported to up-regulate their IL-10 gene expression after PRRSV infection (22,58). Increased 
IL-10 production has been detected in the lungs of PRRSV-infected pigs during monocyte 
accumulation (13,16,25,28,64). Porcine monocytes seem to be a more potent IL-10 producer 
than porcine MDM and immature MDC in response to PRRSV (Fig. 7). The potential of 
porcine monocytes to express IL-10 in comparison to porcine MDM and immature MDC has 
been reported in response to bacterial lipopolysaccharide (LPS), Actinobacillus 
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pleuropneumoniae, Sendai virus, and plasmid DNA (6,7,24,43). The ability of porcine 
monocytes to express IL-10 in response to PRRSV may induce poor T cell response. In pigs, 
monocytes are a more potent inducer of T cell proliferation than MDM and immature MDC 
(6). In humans and mice, T cell stimulating activity of monocyte is reduced after a treatment 
with IL-10 (39,44). IL-10 has been reported to suppress expressions of MHC class II and co-
stimulatory molecules (CD80/CD86) on murine monocytes as well as production of pro­
inflammatory cytokines ie. IL-1, IL-6, IL-12, and TNFa, which are essential for activation of 
APC and induction of T helper 1 response (39,41,44,45,59). In pigs, IL-10 suppresses IFNy 
production by T cells (68). Increased IL-10 production by monocytes after PRRSV infection 
may be a strategy of PRRSV to down regulate pig CMI response. IL-10 has chemotactic 
activity that can attract T cells (44). PRRSV may exploit this activity of IL-10 to attract T 
cells to the infected lungs and lymphoid tissues where monocytes are accumulated and 
intense concentrations of EL-10 are being produced. 
Significantly increased IL-2 gene expression was detected in monocyte and MDM 
cultures infected with virulent PRRSV and stimulated with con A (p<0.05) (Fig. 6). T cells 
from monocyte cultures demonstrated significantly reduced CD25 expression (p<0.05) (Fig. 
3). In mice, IL-2 gene expression is directly correlated with CD25 gene expression 
(31,51,54). Increased IL-2 production enhances CD25 expression in murine T cells 
(31,51,54). IL-2 binds to constitutively expressed |3 and y chains of IL-2 receptor on T cells, 
which then triggers signaling molecules eg. JAK1, Ras, Raf, MAPK, PI3K, E2F, NFKB and 
STAT5 to induce transcription of CD25 gene (4,18,37,67). In pigs, the effect of IL-2 on 
CD25 expression is not known. Some binding motifs for transcription factors used for CD25 
transcription in mice were found in the 5'-upstream region of the porcine CD25 gene (27). 
In-depth study focusing on signaling pathway for porcine CD25 expression is essential to 
elucidate the mechanism used by virulent PRRSV to suppress CD25 expression by T cells. 
In mice, CD25 expression can be reduced by the regulatory effects of suppressors of cytokine 
signaling 1 (SOCS1) molecules, SOCS3 molecules, Shp-1, and CIS1 (3,14,18). In pigs, 
SOCS1 gene expression was reportedly increased in T cells in the recall response to PRRSV 
(50). 
In conclusion, this study reported that PRRSV has the ability to suppress T cell activity. 
The ability was demonstrated by significantly reduced CD25, IFNy, and TNFa expression of 
T cells in response to con A and PMA/I. The suppressive activity associates with virus 
virulence and is mediated by monocytes but not by MDM and immature MDC. The reduced 
expression IFNy and TNFa is mediated by increased expression of IL-10. 
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Chapter 5. General Conclusions 
Discussion 
The work presented in this dissertation has generated new knowledge on cell-
mediated immune (CMI) response to porcine reproductive and respiratory syndrome virus 
(PRRSV). Several kinds of vaccine adjuvants have been tested for their adjuvant property 
for PRRS modified-live virus (MLV) vaccine (Ingelvac® PRRS MLV, Boehringer Ingelheim 
Vetmedica). The CMI responses were correlated with protection from virulent PRRSV 
challenge. The ability of PRRSV to suppress T cell responses was investigated. 
In the first study, which is described in chapter 3, antigen-specific T-cell subsets 
responsible for PRRS MLV vaccination were characterized, using a developed 4-color flow 
cytometry method. Previous methods used to study T cell responses to PRRSV included 
reverse transcriptase (RT)-PCR for cytokine gene expression, ELISA for cytokine 
production, enzyme-linked immunospot (ELISPOT) assay for IFNy production, and 
incorporation of 3H-thymidine and PKH staining for lymphocyte blastogenesis assay. None 
of these assays, except PKH staining, provides data of PRRSV-specific T cell subsets and T 
cell activation, proliferation, or cytokine production at the same time. By the 4-color flow 
cytometry method, five T-cell subsets including CD4+CD8"y8", CD4+CD8+yô", CD4"CD8+yô", 
CD4"CD8+y8+, and CD4"CD8~y5+ and a non T-cell subset (CD4"CD8"yô") were 
simultaneously characterized for surface expression of CD25 molecules and intracellular 
expression of IFNy. The expression of CD25 molecules and of IFNy was assessed after in 
vitro exposure to PRRSV. No up-regulation of CD25 expression was detected in any T-cell 
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subsets after PRRS MLV vaccination. Only CD4"CD8+y8" T cells showed significantly 
increased IFNy expression after vaccination. 
To attempt to improve the CD25 and IFNy responses of T cells to the PRRS MLV 
vaccine, five different vaccine adjuvants (bacterial endotoxin-derived adjuvant, mixed open 
reading frame 5 (ORF5) peptides derived from 5 PRRSV isolates, porcine IFNa, 
polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose, and 
porcine interleukin-12 (IL-12)) were used. Administration of mixed ORF5 peptides at 14 
and 28 days after PRRS MLV vaccination significantly increased IFNy production in CD4" 
CD8+y§+, CD4"CD8~y8+, and CD4~CD8+y8" T cells. Administration of porcine IL-12 at 1 day 
after PRRS MLV vaccination significantly increased IFNy production in CD4+CD8+y8", 
CD4"CD8+y8+, and CD4"CD8+yS" T cells. Significantly increased IFNy expression in 
CD4+CD8+yS\ CD4"CD8+y8+, and CD4"CD8+y8" T cells but not CD4"CD8y8+ T cells were 
correlated significantly with the reduction of lung lesion scores and viremia after virulent 
PRRSV challenge. Administration of porcine IFNa at -1, 0, and 1 day and porcine IL-12 at 1 
day after PRRS MLV vaccination significantly increased CD25 expression in CD4"CD8+y8+ 
T cells. However, the increased CD25 expression did not correlate with protection. None of 
the vaccine adjuvants contributed to the reduction of lung lesion scores and viremia in 
comparison to PRRS MLV alone. 
In the second study, which is described in chapter 4, the ability of PRRSV to suppress 
T cell expression of CD25, IFNy, and tumor necrosis factor alpha (TNFa) was determined by 
flow cytometry in naïve porcine T cells in response to concanavalin A and phorbol 12-
myristate 13-acetate plus ionomycin (PMA/I). Four PRRSV isolates of varying clinical 
virulence and three different types of porcine myeloid antigen-presenting cells (APC) were 
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used. The effects of PRRSV virulence and PRRSV-infected myeloid APC on T cell response 
were not known. Naïve T cells cultured with monocytes infected with virulent PRRSV (VR-
2385, SDSU-73, VR-2332), but not with PRRS MLV (Ingelvac® PRRS MLV, Boehringer 
Ingelheim Vetmedica), demonstrated significantly reduced %CD25+ and %IFNy+ when 
compared to T cells incubated with uninoculated monocyte cultures. T cells cultured with 
monocytes infected with all four PRRSV isolates demonstrated significantly reduced 
%TNFa+. The significant reduction of %CD25+, %IFNY+, and %TNFa+ was not detected in 
T cells cultured with monocyte-derived macrophages (MDM) and immature monocyte-
derived dendritic cells (MDC) infected with any PRRSV isolates. The reduction of T cell 
response in monocyte cultures was not due to PRRSV-induced T cell death. Gene expression 
of IL-10 detected by semi-quantitative RT-PCR was significantly increased in virulent 
PRRSV-infected monocyte cultures after PMA/I, but not con A stimulation, compared to IL-
10 gene expression from uninoculated monocyte cultures. Increased IL-10 gene expression 
contributed to significantly reduced %IFNy+ and %TNFa+, but not %CD25+, as determined 
by an IL-10 neutralization assay. 
Recommendations for Future Research 
The finding that IL-10 contributed to significantly reduced %IFNy+ and %TNFa+ 
provides the direction for development of vaccine adjuvants for PRRS MLV vaccine. The 
vaccine adjuvants for PRRS MLV vaccine should be able to prevent IL-10 production after 
PRRS MLV vaccination. The prevention of IL-10 production might be achieved by the 
utilization ofRNA interference (RNAi) technology. A recent study on RNAi in pigs 
revealed that chemically synthesized small interfering RNA (siRNA) targeted to 
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glyceraldehyde-3-phosphate dehydrogenase (GAPDH) reduced GAPDH transcripts in 
pulmonary alveolar macrophages (PAM) (Zhang et al., 2005). The use of chemically 
synthesized porcine IL-10 siKNA as a vaccine adjuvant might be able to reduce IL-10 
transcript after PRRS MLV vaccination. The prevention of IL-10 production by porcine IL-
10 siRNA may improve CMI responses of pigs to PRRS MLV vaccine. 
The finding that virulent PRRSV suppresses CD25 expression on T cells in an IL-10-
independent manner suggests that there are yet unknown mechanisms of PRRSV to suppress 
CMI responses. To elucidate these mechanisms, an in-depth study of signaling pathways of 
porcine CD25 expression is essential. The knowledge of mechanisms used by PRRSV to 
suppress CD25 expression might be utilized for development of vaccine adjuvants that can 
interfere with the pathway stimulated by the virus. 
The effect of PRRSV of varying levels of virulence on CMI responses has not been 
determined in vivo. The knowledge of PRRSV virulence effect on CMI responses in vivo 
may help explain differential clinical severity among PRRSV strains. CMI response to 
virulent PRRSV may be delayed, compared to CMI response to low virulent PRRSV. The 
delayed CMI response may facilitate virulent PRRSV replication and cause more damage to 
virus-infected cells. 
Differential suppressive activity of PRRSV on CD25, IFNy, and TNFa expression on 
T cells may be useful for selection of candidate strains for PRRSV vaccine. The candidate 
PRRSV vaccine strains should have neither clinical virulence nor T cell suppressive activity. 
The lack of T cell suppressive activity will improve the CMI response of pigs to the vaccine. 
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